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Abstract 
     Speedy (Spy1A) is a novel cell cycle gene whose product binds to cyclin-dependent 
kinase-2 (CDK2) and activates its kinase activity to promote cell cycle progression 
through a cyclin independent mechanism. Spy1A is expressed naturally at high levels in 
the proliferating mammary gland, and aberrant overexpression of Spy1A results in 
precocious mammary development and eventually tumorigenesis in vivo. Induction of the 
mammary oncogene c-Myc upregulates Spy1A and I further demonstrate that Spy1A 
protein levels are elevated in mammary tissue and breast tumors derived from MMTV-
Myc transgenic mice. Spy1A knockdown in F5A1-2 cell lines led to downregulation of 
cyclin-dependent kinase inhibitors (CKI) p21 and p27, a 23% reduction in proliferation 
rate, and a shift in cellular phenotype to a spindle-like/fibroblastic morphology. Together, 
findings support that Spy1A plays a functional role in mammary-related c-Myc signal 
transduction, and acts downstream of ERα, c-Myc, and the MAPK cascade to regulate 
proliferation, mammary development, and carcinogenesis. 
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Introduction 
     Amid all cancers known to afflict the Canadian population, breast cancer (BC) is 
documented as the “second leading cause of cancer mortality” among females to date.
1
 
Despite vast research and clinical efforts to reduce mortality rates in BC patients, 22 700 
Canadian women are predicted to develop the disease in 2009 alone.
1
 Current knowledge 
of the molecular signatures and biochemical pathways that govern BC initiation and 
progression is far from comprehensive and requires further expansion in order to identify 
putative biomarkers that undoubtedly predict the correct therapeutic course of action to 
take with each patient. Due to the heterogeneous nature of cell types which cooperate to 
form a functional post-natal mammary gland,
2
 the various clinical forms of BC that may 
arise are currently distinguished based on prognostic criteria such as histological 
phenotype, steroid and growth factor receptor status, and tumor ability to metastasize to 
neighbouring lymph nodes.
3
 In order to fully understand the various molecular 
mechanisms underpinning the evolution of mammary tumorigenesis, post-pubertal 
mammary gland development is often looked upon to highlight critical signaling 
pathways that possess the inherent capacity to mutate and/or become deregulated in BC.
4
 
 
I. Mammary Gland Ultrastructure is Optimized for Stromal-Epithelial Crosstalk During 
Development. 
     Defined as an exocrine organ,
5
 the mammary gland is essentially comprised of stromal 
and epithelial tissue compartments
6
 that intimately collaborate during embryonic and 
adult mammopoiesis, especially during ductal tree formation.
7
 Throughout ductal 
morphogenesis at pubertal onset,
8
 cells of epithelial origin are organized into mammary 
ductal outgrowths that primarily invade into the surrounding stromal fat pad and continue 
to branch outwards into functional alveolar subunits.
6
 In turn, alveolar epithelia are 
populated by luminal secretory cell types that are capable of producing milk
 
upon 
hormonal stimulation. Additionally, alveoli are enclosed by basal myoepithelial networks 
that are contractile in nature and aid in milk secretion.
6
 In stark contrast, mammary 
stromal mesenchyme
7
 is predominantly assembled from adipocytes, and is more sparsely 
populated by fibroblasts, haematopoietic-derived cell types, nutrient-rich blood vessels, 
and neurons.
6
 The extracellular matrix (ECM) reinforces structural support of the stroma, 
2 
 
and consists of laminin, fibronectin, collagen, and proteoglycans, in addition to other 
proteins.
7
 
 
II. Continuous Cellular Turnover Features Throughout Post-natal Mammopoiesis. 
     Prenatal mammary embryogenesis denotes a period of robust developmental activity 
directed under molecular
9
 and epigenetic mechanisms (chromatin remodelling)
10
 that, in 
turn, cooperate to induce mammary bud formation
11
 and rudimentary ductal precursor 
establishment.
8,10
 Shortly after birth, post-natal maturity begins with a brief episode of 
developmental quiescence that eventually halts upon re-initiation of ductal 
morphogenesis in response to ovarian-produced steroidal hormones delivered to a 
pubescent mammary gland.
8-9,11 
More explicitly, pubertal onset is marked by increased 
ovarian follicular activity and responds to elevated production of 17b-estradiol (E2).
12-13
 
In turn, endocrine transport of ovarian estrogen to an immature mammary gland 
potentiates mammary ductal elongation and outgrowth
 
by inducing the mitogenic action 
of both epithelial and stromal compartments.
12,14-15
 The establishment of a functional 
ductal tree commences with ductal outgrowth and terminal end bud (TEB) formation 
during early pubertal stages.
6,16 
Located within the leading edge of extending ducts, TEBs 
are defined as highly proliferative club-shaped units that serve a two-fold purpose: (a) 
invasion of the surrounding connective tissue to promote ductal elongation,
6,16
 and (b) 
production of ductal side branches upon TEB clefting.
16
 TEBs transition into non-
dividing terminal end ducts (TEDs) and alveolar precursor structures upon complete 
filling of the mammary fat pad with mature ductal networks during late puberty.
17
  
     Once maturity is established, the adult virgin mammary organ retains the ability to 
cycle through four  developmental stages: virgin, pregnancy, lactation, followed by 
involution and reversion to a virgin-like state.
6
 During early pregnancy-induced lobulo-
alveolar development,
11
 elevated expression of prolactin, placental lactogens, and 
progesterone
6
 results in escalated rates of luminal epithelial proliferation, and promotes 
functional differentiation of alveolar precursor cells into specialized structures proficient 
in milk release.
6
 Parturition-induced lactogenesis functions to nourish neonates
8
 through 
alveolar milk production and secretion of colostrum into enlarged luminal ducts.
6
 Neonate 
3 
 
weaning initiates extensive luminal alveolar cell death (apoptosis) and epithelial 
remodelling during involution,
 
a process lasting for several days to allow for re-
instatement of the mammary gland to a virgin-like appearance.
6,16
  
 
III. Conserved Developmental Programs Regulate Mammary Remodelling in a Time-
dependent Fashion.  
     Throughout post-natal mammary development, rapid transitioning through cell 
growth, proliferation, apoptosis, and terminal differentiation is tightly coordinated under 
temporal activation of gene networks at discrete developmental time points.
4,6
 Molecular 
studies utilizing high through-put analysis and gene expression profiling of mouse 
mammary glands isolated at various stages of development have revealed three critical 
regulators of adult mammopoiesis: estrogen, extracellular signal-regulated kinases (ERK) 
1 and 2, and c-Myc, the protein product of the c-myc gene.
18-21
 Simultaneous increase of 
ERK1/2 and c-Myc is prevalent throughout the third, sixth, and seventh weeks of murine 
pubertal development, whereas estrogen-regulated signaling is downregulated during 
third and fourth weeks of early puberty, followed by subsequent upregulation during 
week 5, and downregulation during weeks 6-7 (Fig.1a).
20
 Throughout the final weeks of 
late puberty, elevated ERK1/2 and c-Myc expression (Fig.1a) precede pubertal 
completion.
20
 In a separate report, Golipour and Myers et al. (2008) demonstrated that 
fully developed adult virgin mammary glands express significant levels of Spy1/RINGO 
(Spy1) A protein and mRNA, thereby correlating to periods of robust cell proliferation 
(Fig.1c).
22
 Pregnancy inception further stimulated Spy1A expression, which peaked at 
pregnancy day 6 and steadily declined during late pregnancy and lactation events 
(Fig.1c).
22
 In addition, c-Myc activity is predominant throughout all periods of lactation 
and involution, and its pattern of expression opposes that of estrogen-regulated signaling 
(Fig.1b).
20
 ERK1/2 expression, on the other hand, continually fluctuates between active 
and inactive states during lactation and involution (Fig.1b).
20
 Conclusively, involution is 
characterized by a potent increase in Spy1A activation (Fig.1c), a period of gland 
restoration marked by intensive apoptotic events.
22
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Figure 1. Conserved developmental programs regulate mammary gland remodeling in 
a time-dependent fashion. (a) As previously reported by Andrechek et al. (2008), 
normalized enrichment scores (NES) derived from Gene Set Enrichment Analysis were 
identified during weeks 3-7 of pubescence for each of the following data sets, and 
represent relative levels of gene expression at each week of pubertal development: 
ERK1/2 MAPK pathway (blue line); Myc HUVEC SAGE ARRAY UP (purple line); and 
BC estrogen signaling (red line).
20
 Quadrants highlighted in blue indicate gene 
upregulation based on NES values reported for each developmental stage.
20
  (b) NES 
values reported by Andrechek et al. (2008) were reported for days 1, 3, and 7 of lactation, 
and during days 1-4 of involution for the following data sets: ERK1/2 MAPK pathway 
(blue line); BC estrogen signaling (red line); and Myc Database Up (purple line).
20
 
Quadrants highlighted in blue indicate gene upregulation based on NES values reported 
for each developmental stage.
20
 (c) As previously demonstrated by Golipour and Myers et 
al. (2008), the normalized densitometry ratio of Spy1A:Actin protein expression is 
depicted for virgin; pregnancy days 6, 10, and 15; lactation; and involution stages of 
mammary development, and represent relative levels of protein expression at each 
developmental stage.
22
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IV. The Tumor Promoting Role of ERa and its Connection to Antiestrogen Resistance. 
     A master hormonal regulator of diverse cellular processes, the steroidal action of 
estrogen specializes in mediating cellular proliferation and mammary development via 
estrogen receptor (ER) activation.
12-13
 Classified under the nuclear receptor super family, 
the estrogen receptor exists as two isoforms, namely ERa and ERb, both of which 
function as global transcription factors.
12,23 
The differential expression of ERa and ERb is 
apparent in various tissues.
12
 In wild type murine mammary glands, for instance, ERa 
predominantly localizes to luminal epithelial cell populations and is virtually absent in the 
surrounding myoepithelium,
23
 whereas ERb localizes to both compartments.
12
 Estrogen 
receptor isoforms also differ in function when coexpressed in ductal cells of the 
mammary epithelium, such that ERb represses ERa- stimulated proliferation and is 
thought to promote differentiation instead.
12
  
     Approximately 75% of diagnosed mammary neoplasias probe positive for estrogen 
receptor status
23
 and are treated initially with antiestrogens,
24
 aromatase antagonists such 
as letrozole,
25
 and more commonly, selective estrogen receptor modulator (SERMs) such 
as tamoxifen (TAM).
12,24
 Thirty percent of aggressive ERa-positive tumors
23
 eventually 
circumvent the growth inhibitory action of ER-targeted therapies
23-24,26 
and prompt 
chemotherapeutic agents like tamoxifen to delineate into proliferative stimulants of 
cancer cells.
25
 Termed antiestrogen or tamoxifen resistance, this process often correlates 
clinically with a significant decrease in patient outcome.
23 
The complex nature of estrogen 
signaling and its pervasive regulation over an extensive array of cellular mechanisms 
during normal mammary gland development and tumorigenic onset further complicates 
our understanding of how tamoxifen resistance may initially arise.
27
 Although the full 
scope of estrogenic action has yet to be defined, several studies have predicted a role for 
estrogen-dependent mechanisms in the development of tamoxifen resistance.
27
 For 
instance, the ERK1/2 pathway has been shown to trigger expression of intermediary 
target genes known to be implicated in tumor invasion, and is markedly elevated during 
mammary tumor progression.
15
 ERK1/2 functions to potentiate ER transcriptional activity 
via direct phosphorylation and activation of ER, and may alter ER localization, leading to 
an overall increase in mitogenesis and cell survival.
15
 Furthermore, elevation of ERK 
7 
 
levels in estrogen-expressing mammary tumors typically reduces patient outcome and 
contributes significantly to tamoxifen resistance.
15
 Conversely, mitogen-activated protein 
kinase (MAPK) activation of ERK isoforms may result in the phosphorylation and 
activation of ER coactivators instead of associating directly with ER.
15
  
     Analogous to MAPK, c-Myc – a nuclear transcription factor whose intracellular 
activity is contingent upon c-Myc dimerization with binding partner Max – functions as a 
direct downstream transcriptional target of ERa, and is traditionally defined as a central 
mediator of estrogen signaling.
27
 Also, the c-Myc promoter harbours an estrogen response 
element (ERE), a DNA binding region deemed to be essential for ERa association with 
the c-Myc transcript.
27
 Consequently, ERa induces c-Myc expression 15 minutes post-E2 
exposure.
27
 Furthermore, ERa and c-Myc are classified as potent mitogenic stimulants 
proficient in stimulating irrepressible BC tumor proliferation, and c-Myc activation is 
further required by ERa to promote cell cycle transitioning through G1/S phase.
27
 In this 
way, c-Myc potentiates cellular endpoints similar to those induced by ERa.
27
 Upon 
transcriptional activation, c-Myc regulates a plethora of target genes, including cyclin E/ 
CDK (cyclin-dependent kinase) 2 complexes through a mechanism that involves 
suppression of cell cycle inhibitor (CIP1) p21.
27
 Moreover, in response to long-term E2 
withdrawal, c-Myc gene levels increase.
9
 C-Myc has further been documented to partially 
re-initiate cell proliferation in MCF7 BC cell lines pre-treated with antiestrogens, and 
therefore potentiates cell cycle progression even in the continued presence of estrogen 
inhibitors.
9
 Based on these data, a central role has been implied for c-Myc in the 
development of antiestrogen resistance.
28
     
 
V. Hyperstimulation of MAPK Signaling During Mammary Tumorigenesis. 
     The MAPK family comprises a broad group of signal effectors able to respond to 
numerous receptor-bound ligands under differential cellular conditions.
29
 Four distinct 
MAPK networks have been identified to date, and include ERK1/2, c-Jun-amino-terminal 
kinase, p38, and ERK5.
29 
Under stringent molecular control, MAPK cascades are best 
known for their rapid ability to transduce extracellular growth factor, hormonal, and stress 
stimuli into physiological outputs such as cardiovascular development; differentiation; 
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mesoderm formation; cell cycle initiation; and cellular proliferation.
29-30
 Upregulation of 
MAPK signaling has also been implicated in tumor formation and migration.
29-30
 
Additionally, select mammary epithelial cell systems have illustrated the importance of 
Raf/MEK/ERK activation during Ras-mediated metastatic progression,
31
 and increased 
Ras expression and activity is often identified in clinical cases of cancer.
32
 Consistent 
with the notion that ERK activity stimulates cell entry into G1 following G0 arrest,
30
 
human mammary tumor cell lines that no longer respond to estrogen contain elevated 
levels of ERK1/2.
12
 More importantly, the ERK/MAPK pathway counteracts tamoxifen-
mediated inhibition of the cell cycle, and favours evolution of tamoxifen resistance.
33
   
     Canonical ERK1/2 signaling is induced upon receptor-mediated recognition of 
extracellular ligands, and leads to immediate activation of Grb2, a membrane-localized 
adaptor molecule known to tether itself to the guanine nucleotide exchange factor SOS.
30
 
Together, Grb2 and SOS indirectly promote MAPK signal transduction through Ras, a 
small molecule tumor promoter with intrinsic GTP binding capacity.
30,34 
Consequent 
stimulation of MAPK results in the feed-forward activation of cytoplasmic and nuclear 
target genes notorious for their pro-mitogenic effects.
30
  
     MAPK activity is contingent upon tyrosine and serine/threonine phosphorylation.
30
 
Raf-1, a serine and threonine kinase, is recruited to the plasma membrane upon direct 
association with the N-terminus of Ras
30
 and is positively regulated by phosphorylation.
35
 
In turn, Raf-1 activates three MEK isoforms (MEK1a, MEK1b, MEK2), a group of 
highly conserved serine/threonine kinases that require only serine phosphorylation to 
function.
30
 In an effort to amplify the MAPK signal, the MEK family phosphorylates two 
downstream substrates ERK1 and ERK2 on select threonine and tyrosine residues.
30
 In 
turn, kinase activation of ERK1/2 mediates its movement into the nucleus, and stimulates 
ERK1/2 to phosphorylate target substrates on serine and threonine residues commonly 
flanked by proline.
30
 Direct targets include the promoter of transcription factors such as c-
Myc,
29-30,36-40 
and ERKs are further capable of signaling back to upstream MAPK 
members (SOS, Raf-1, MEK).
30
 ERK2 interacts with and hyperphosphorylates Raf-1 on 
five key residues bordered by proline in order to prevent association of Raf-1 with Ras, 
and to cripple Raf-1 activity.
35
 Moreover, ERK2 phosphorylation of Raf-1 relies on 
upstream MEK activity in order to deactivate its substrate, and represents a negative 
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feedback loop utilized by MAPK cascades to temporally regulate Ras and cellular 
responses to mitogens.
35
 Negative MAPK regulation is featured also in primary 
fibroblasts and chronic myeloid leukemia cells, where Ras uncharacteristically inhibits 
cell growth through Raf-1/MEK/ERK activation of the tumor suppressor p21.
34
 C-Myc is 
able to restore cell proliferation upon suppression of Ras activity, and thus functions here 
to inhibit MAPK signaling.
34
 
 
VI. Aberrant Regulation of c-Myc Activity Encourages Formation of Aggressive 
Mammary Carcinomas. 
     C-myc – a potent oncogene, phosphoprotein, and transcription factor – governs a 
plethora of cellular events
41-42
 including proliferation, development, and apoptosis.
4,43
 
Common to both humans and mice, the c-myc gene comprises three exons altogether, 
although protein synthesis is mainly directed through transcription of second and third 
exons.
42
 The protein product c-Myc is predicted to possess a molecular weight of 49 kDa 
(439 aa), however antibody detection identifies various c-Myc isoforms that range from 
62 to 67 kDa in size.
42
 Biochemical studies of COS-7 cells transfected with numerous 
mutated c-Myc constructs have uncovered a partial role of amino acid regions 106-143, 
320-368, and 370-412 for Myc subcellular localization.
42
 More importantly, regions 105-
143 and 321-439 must remain intact for c-Myc to function properly.
42
 C-Myc is 
predominantly localized to the nuclear component of cells where it retains a relatively 
short half life of approximately 15-30 minutes,
42
 consistent with its classification as an 
immediate early gene.
44
 Nuclear translocation typically results in transcriptional 
activation of Myc-responsive target genes through functional binding of c-Myc and its 
dimerization partner Max to canonical palindromic DNA motifs/E-boxes (CACGTG).
45
 
Alternatively, interaction between c-Myc and DNA may occur through recognition of 
different promoter response elements.
45
  
     As a direct consequence of abnormal oncogenic activity in the tumor 
microenvironment, mammary-derived neoplasias are continually credited for their elusive 
ability to circumvent regulatory mechanisms that otherwise direct tissue homeostasis and 
the maintenance of developmental programs.
4,42 
C-Myc gene amplification has been 
described in 5-15% of all human BC cases, and strongly correlates with reduced patient 
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survival and aggressive tumor phenotypes.
4
 Identified in a broad spectrum of human 
tumors, the key mechanisms of c-Myc-induced tumorigenesis include abnormal c-Myc 
expression and activity, and its chromosomal transolocation.
45
 Transgenic murine models 
engineered to overexpress mammary c-Myc under the promoter control of the mouse 
mammary tumor virus long-terminal repeat (MMTV-LTR) consistently give rise to 
invasive mammary adenocarcinomas and demonstrate further anomalies in adult 
mammopoiesis.
4
 Furthermore, approximately 50% of virgin females give rise to 
stochastic mammary adenocarcinomas within a 7-14 month period following birth, in 
addition to 100% of females that have undergone two or more pregnancies.
46-47
  
Development of the transgenic MMTV-Myc mouse model was previously described by 
Sinn, et al. (1987).
46,48
 Transgenic mice target constitutive overexpression of human c-
Myc to mammary epithelial cells under MMTV-LTR promoter control.
46
 Virgin mice 
particularly fall victim to deregulations in lobuloalveolar development in the mammary 
gland.
4
 Aberrations in c-Myc-overexpressing mammary glands encompass the premature 
withdrawal from postpartum lactation due to enhanced epithelial differentiation, and 
activate pregnancy-induced lactation precociously, which is then followed by the 
cessation of milk synthesis and untimely onset of gland remodelling during involution.
4
 
Therefore, disrupted lactation in MMTV-Myc mothers causes subsequent neonatal death 
as early as 24 hours post-delivery.
4
   
 
VII. Molecular Mechanisms Underlying Cell Cycle Control Prevent Uncontrollable Cell 
Proliferation.   
     The cell division cycle is regulated by a series of CDKs whose alternating expression 
levels and association with cyclins are fundamental to the progression of cell cycle 
events.
18,49
 Cyclin synthesis and degradation is paramount for the temporal regulation of 
CDKs and their ability to interact with and phosphorylate target substrates during key cell 
cycle phases: cyclin D/CDK4 and cyclin D/CDK6 at G1; cyclin E/CDK2 at G1/S; cyclin 
A/CDK1 at S/G2; and lastly, cyclin B/CDK1 at G2/M.
50
 CDKs are controlled post-
transcriptionally through various means: several examples include direct/indirect 
partnership with a repertoire of nuclear co-regulators, localization, proteolysis, as well as 
cyclin-mediated phosphorylation.
18
 CDK molecular structure reveals three critical 
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phosphorylation sites, two of which are inhibitory to CDK function, and one that 
positively directs CDK activity in the absence of inhibitory cyclin dependent kinase 
inhibitors (CKIs).
18
 Furthermore, interaction between CDKs and CKIs results in cell 
cycle arrest
51
 at G1/S and G2M checkpoints,
52
 and ultimately alerts cells to correct 
aberrations in DNA content and integrity prior to mitosis.
52
 CKIs are classified into two 
main subtypes, namely the CIP/KIP and INK4 families.
51
 The first group negatively 
mediates the transition through G1/S and is comprised of p21, KIP1 (p27), and KIP2 
(p57) proteins, whereas the INK4 group directly targets CDK4 and CDK6 to thwart 
complex formation with cyclin D.
51
  
     Endogenous activation of nuclear p27 contributes to cell cycle arrest at G1 by directly 
binding to and inhibiting cyclin E/CDK2.
32
 Subsequent exposure to mitogens relieves p27 
repression of cyclin E/CDK2 and stimulates cell movement through G1/S by suppressing 
p27 function.
32 
Likewise, mitogen-dependent trimerization of p27/cyclin D/CDK4 limits 
the amount of unbound p27 substrate available to negatively associate with cyclin 
E/CDK2.
53
 During G1/S transitioning, ubiquitin-mediated proteolysis, cytoplasmic 
relocalization, and phosphorylation of p27 also remove its inhibitory action on cyclin 
E/CDK2 activity, and consequently promote the onset of DNA replicative events.
32,53
 
Prior to S-phase entry, successful passage through the restriction (Re) checkpoint and its 
regulatory pathways
49
 permits cells to deviate from the cell stimulatory effects of G1-
acting mitogens.
54
 In this way, entry through Re ensures the success of cellular DNA 
replication
49 
and allows for cell division to proceed through mitosis
55
 uninterrupted, in the 
absence of apoptotic and DNA damaging stimuli.
56
 Clinical relevance of p27 
downregulation ultimately correlates with reduced patient survival, favours escape from 
estrogen-related signaling, and contributes to mammary tumorigenesis in breast cancer 
cell lines.
32
  
 
VIII. Intact Nuclear Function of Spy1A Regulates Cell Cycle Progression Through G1/S 
Phase.  
     Spy1/RINGO (Rapid INducer of G2/M progression in Oocytes) was first discovered to 
be an activator of G2/M and a potent enhancer of oocyte maturation in Xenopus (X-
Spy1).
18-19,50,57
 Spy1A, the human homologue, shares 40% homology with X-Spy1.
49
 
12 
 
Spy1A is classified as a novel cell cycle gene whose product binds to CDK2 and activates 
its kinase activity to induce cell cycle progression through a cyclin-independent 
mechanism,
49
 and to promote cell movement into DNA synthesis.
58
 Pinpointed to the 
nucleus,
19
 upregulation of Spy1A inevitably stimulates the precocious entry of cells into 
S-phase by shortening G1,
 
and thereby amplifies rates of cell proliferation.
18,53
 Moreover, 
somatic cell culture has revealed an ability for Spy1A to rescue mammalian cells from the 
deleterious effects of DNA damage.
19
 In contrast, in vitro studies have demonstrated that 
transient RNA interference (RNAi) knockdown of Spy1A results in cell cycle arrest at 
G1/S phase as evidenced by declining cell populations undergoing G2/M transition.
18-19
 
Furthermore, all Spy1 forms contain a conserved 140-aa Speedy/RINGO box required 
and sufficient for CDK association and stimulation.
18-19
 Unique only to Spy1A, the CDK-
binding domain is flanked by a C-terminal CDK activating domain, as well as an N-
terminal domain whose function is mostly unknown but is thought to mediate Spy1A 
protein expression.
18-19
       
     In addition to Spy1A, which has two transcript variants – A1 and A2, Cheng et al. 
(2005) previously classified three distinct Spy1 homologues in mammals: Spy1B, C, and 
D.
18
 Other homologues have been identified since then, including Spy1E.
19 
Members of 
the Spy1 family may override select cell cycle regulatory mechanisms, and certainly 
respond with less intensity to CKI-mediated cell cycle effects.
18
 For instance, 
Cdk2/Spy1A complexes generally override p21-induced cell cycle arrest.
59
 In a yeast 
two-hybrid screen conducted by Porter et al. (2003), direct binding of p27 to Spy1A was 
identified and confirmed in vitro/in vivo.
53
 The direct interplay between Spy1A and p27 is 
contingent upon p27 residues 43-128, and endogenous p27 expression leads to elevated 
Spy1A/CDK2 association, thus demonstrating the ability of Spy1A to overrule p27-
mediated inhibition of cyclin E/CDK2 during G1/S.
19,53,60
 Shortly thereafter, McAndrew 
et al. (2007) established that CDK2 requires Spy1A to phosphorylate p27 (T187), thereby 
encouraging degradation of p27.
60
  
 
IX. Spy1A Promotes Mammary Tumorigenesis in Various Cell Culture and Animal 
Models. 
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     Presence of Spy1A has been reported in both mouse and human tissues, although 
amino acid composition varies substantially between inter-species homologues.
19
 Spy1A 
is ubiquitously distributed throughout numerous cell and tissue types, and greatest levels 
occur in testicular organs and other tissues of meiotic origin.
18-19
 Recently, the Spy1A 
isoform was shown to be expressed naturally at high levels in the proliferating mammary 
gland, where it was found to predominantly localize to luminal epithelial cells, and 
exhibited decreased expression in myoepithelial and adipose tissue as evidenced by 
immunostaining (Mus musculus).
22
 When aberrantly overexpressed, Spy1A activity 
resulted in precocious development and eventually mammary tumorigenesis in vivo.
22
 In 
addition, Spy1A mRNA and protein levels were shown to increase substantially following 
induction of c-Myc using a Myc-ER
TM
 mouse embryonic fibroblast (MEF) inducible cell 
system.
22
 Upregulation of Spy1A transpired in the absence of de novo protein synthesis, 
suggesting that c-Myc may act directly to trans-activate Spy1A expression.
22
  
     The Spy1A promoter remains to be elucidated, although progress towards its 
determination is currently underway. Phylogenetic footprinting is defined as a 
bioinformatics method utilized to unearth the transcriptional co-regulators of a given gene 
by piecing together the necessary basal and modular response elements required for 
transcription initiation.
61-62
 Among other procedures, this approach often utilizes 
computational alignment in order to compare a promoter sequence of interest to 
comprehensive databases that house consensus DNA binding motifs recognized by 
transcription factors.
61-62
 Previously, the putative promoter sequence of Spy1A was 
subjected to phylogenetic footprinting, and as a result, we have uncovered prospective 
nuclear factors that participate in regulating Spy1A transcription depending on context-
specific ligand activation (summarized in Fig.2). Of particular interest, both c-Myc and 
ERa response elements are found in close proximity to one another and hypothetically 
localize to the Spy1A promoter. Taken together, these data support the hypothesis that 
Spy1A functions downstream of the c-Myc signalling pathway to regulate c-Myc effects 
on cell proliferation, mammary gland development, and mammary tumorigenesis. 
     Signaling cascades are often initiated by activation of one or more receptors through 
ligand binding interactions. Within a mammary gland paradigm, we propose a pathway  
14 
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Figure 2. The putative promoter sequence of Spy1A. The predicted promoter sequence 
of Spy1A was aligned to various online databases that house consensus DNA binding 
motifs most frequently recognized by transcription factors (phylogenetic footprinting 
method). In reference to the transcription initiation start site (at position 0), the nucleotide 
position of each transcription factor response element is reported below each transcription 
factor. Two independent TATA boxes are illustrated at positions -615 and -100. ERa and 
c-Myc response elements are located in close proximity to one another. 
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that is kick started by estrogen binding to ERa. Estrogen receptor activation stimulates 
the MAPK pathway via Ras, and subsequently activates c-Myc. Following nuclear 
migration, c-Myc is thought to have two potential cellular outcomes. First, c-Myc may 
bind directly to a response element on Spy1A (particularly within the putative promoter 
region). Second, c-Myc has been shown to transiently activate CDK2 directly, and thus 
may have an indirect effect on Spy1A expression and regulation, both during 
development and carcinogenesis. Therefore, it is thought that c-Myc mediates the 
promotion or initiation of mammary gland oncogenesis in part through Spy1A (Fig.3).  
     The purpose of this study was two-fold: (a) first, I sought to determine the essentiality 
of Spy1A for mammary gland development, and further aimed to elucidate the degree to 
which Spy1A mediates c-Myc induced tumorigenesis; (b) second, I sought to determine 
the effects of constitutively active Spy1A on early mammary gland developmental events. 
   
Objective 1: To determine the essentiality of Spy1A for post-natal mammary gland 
development, and to further clarify whether Spy1A mediates c-Myc induced 
tumorigenesis. To uncover the importance of Spy1A for post-natal mammopoiesis and c-
Myc induced mammary oncogenesis, five novel short hairpin (sh) RNA constructs were 
designed against various regions of the mouse Spy1A homologue, and were subsequently 
utilized to assess the effects of Spy1A knockdown in vitro (cellular proliferation assays) 
and in vivo (mammary fat pad transplantation assays) in primary mammary tumor cell 
lines overexpressing c-Myc under control of the MMTV promoter.  
 
Objective 2: To determine the effects of Spy1A overexpression on early mammary gland 
development. Evidence suggests that Spy1A accelerates mammary tumorigenesis and 
postnatal mammary development.
22
 Investigating the role played by Spy1A during 
embryonic formation of the mammary gland within the MMTV-SV (simian virus) 40-
Spy1A transgenic murine model may shine light on these important observations.  
     Ultimately, this study aims to provide insight into key developmental and cell signaling 
events regulating formation of the mammary gland. Results from this work will contribute 
toward our greater understanding of the potential factors that may initiate and/or assist 
17 
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Figure 3. Proposed signaling mechanism thought to activate Spy1A expression during 
mammary gland development and tumorigenesis. In a mammary specific context, upon 
receiving mitogenic cues from estrogen, ERa is stimulated and further promotes MAPK 
pathway activation; in turn, the MAPK machinery is thought to induce c-Myc expression, 
followed by activation of Spy1A. Following nuclear migration, c-Myc is thought to have 
two potential cellular outcomes. First, c-Myc may bind directly to its response element on 
Spy1A (particularly within the putative promoter region). Second, c-Myc has been shown 
to transiently activate CDK2 directly, and thus may have an indirect effect on Spy1A 
expression and regulation, both during development and carcinogenesis. Therefore, it is 
thought that c-Myc mediates the promotion or initiation of mammary gland oncogenesis 
in part through Spy1A. 
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the progression of human breast cancer, in addition to de novo/acquired antiestrogen 
resistance. The mechanism(s) that ERa-positive mammary tumors utilize to develop 
resistance to antiestrogens has been partially evaluated, and constitutes a major clinical 
barrier in the successful treatment of BC patients currently. Our data further implicate 
the involvement of Spy1A during the acquisition of an antiestrogen resistant tumor 
phenotype, thereby potentiating cellular proliferation in the presence of antiestrogen 
treatments like tamoxifen. Although much work remains to be completed, results derived 
from this study suggest that Spy1A may be targeted therapeutically in order to effectively 
reduce the aggressiveness of ERa-positive mammary tumors that have undergone 
tamoxifen resistance.   
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Materials and Methods 
I. Vector DNA Constructs.  
     pLB was purchased from Addgene (MA, USA). Flag-Spy1A-pLXSN plasmid 
construction was described previously by Porter et al. (2003).
53
 The MMTV-SV40-TRPS-
1 vector was provided as a kind gift from Dr. Gabriel E. DiMattia. 
     pLB represents a lentiviral vector that utilizes the mouse U6 promoter to express short 
hairpin RNA (shRNA), and the cytomegalovirus promoter to express green fluorescent 
protein (GFP) in murine cell systems (Fig.4). GFP fluorescence served as a positive 
indicator for induction of RNAi. Conventional restriction enzymes HpaI (Cat. No. 
ER1031) and XhoI (Cat. No. ER0691) (Fermentas, Ontario, Canada) were utilized to 
linearize pLB. Available online as free software (http://www.oligoengine.com), the 
program OligoEngine Workstation 2 was utilized to design five novel shRNA constructs 
directed against unique regions of the mouse Spy1A homologue (NCBI_70891), in 
addition to a scrambled shRNA construct chosen for its inability to recognize and target 
Spy1A for RNAi-mediated degradation (Fig.5). Forward and reverse sequences listed in 
the 5’ to 3’ direction are provided in Fig.5 for scrambled and Spy1A shRNA constructs. 
Constructs flanked by HpaI and XhoI restriction sites were synthesized by Sigma-
Genosys Canada (Sigma-Aldrich, Ontario, Canada). Note that only constructs three and 
four target the mouse Spy1A protein isoform within the Speedy/RINGO box (amino acids 
66-206). Construct two was subsequently subcloned into pLB and designated shSpy1A. 
Similarly, the scrambled construct was subcloned into pLB and designated shCntl. Since 
shRNA constructs do not equally or effectively silence target gene activity, the selectivity 
of construct two for silencing Spy1A transcriptional activity may be confirmed in future 
experiments by cloning and utilizing all five Spy1A shRNA constructs designed to date.  
 
II. Site-directed Mutagenesis (SDM).  
     SDM primers A424 and A425 were designed against Flag-Spy1A-pLXSN to flank the 
vector region containing a putative EcoRI site, and were synthesized by Sigma-Genosys 
(Sigma-Aldrich):  
 forward primer (A424): 
  5’-GCCAGAATTCGATTTATGCATGTTGTTTACTGAGC-3’ 
21 
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Figure 4. Vector map of pLB. The vector composition of pLB (Addgene) was obtained 
from the company website (http://www.addgene.org) and is illustrated here as a point of 
reference. Total size of the pLB vector backbone is estimated to be 8500 nucleotides. 
Each shRNA construct was subcloned into pLB through insertion at the HpaI (3316 bp) 
and XhoI (3331) restriction sites (black box). GFP expression is directed separately from 
shRNA expression, and is mediated through CMV promoter control, whereas shRNA 
expression is mediated through the mouse U6 promoter. 
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Mouse Specific shRNA Constructs
Top Strand 5’-GTCTGAAACGTCCTATTCTTTCAAGAGAAGAATAGGACGTTTCAGACG-3’
Bottom Strand 5’-GATCCGTCTGAAACGTCCTATTCTTCTCTTGAAAGAATAGGACGTTTCAGACCG-3’
Top Strand 5’-GAATCATACAGCGCCAGGAATTCAAGAGATTCCTGGCGCTGTATGATTG-3’
Bottom Strand 5’-GATCCAATCATACAGCGCCAGGAATCTCTTGAATTCCTGGCGCTGTATGATTCCG-3’
Top Strand 5’-GTATCTGGCTAATACGGTTTTCAAGAGAAACCGTATTAGCCAGATACG-3’
Bottom Strand 5’-GATCCGTATCTGGCTAATACGGTTTCTCTTGAAAACCGTATTAGCCAGATACCG-3’
Top Strand 5’-GCAACCCATTACATCTGGCATTCAAGAGATGCCAGATGTAATGGGTTGG-3’
Bottom Strand 5’-GATCCCAACCCATTACATCTGGCATCTCTTGAATGCCAGATGTAATGGGTTGCCG-3’
Top Strand 5’-GTGACACAGGAGAGCTAATTTCAAGAGAATTAGCTCTCCTGTGTCACG-3’
Bottom Strand 5’-GATCCGTGACACAGGAGAGCTAATTCTCTTGAAATTAGCTCTCCTGTGTCACCG-3’
Scrambled Negative Control
Top Strand 5’-AGTGTGCCTACATCTCTTTCAAGAGAAGAGATGTAGGCACACTG-3’
Bottom Strand 5’-GATCCAGTGTGCCTACATCTCTTCTCTTGAAAGAGATGTAGGCACACTCG-3’
1
2
3
4
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Speedy/RINGO box 
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Figure 5. Sequence and location of each Spy1A shRNA construct. (Top) Five novel 
shRNA constructs were designed to target the mouse Spy1A isoform at the indicated 
amino acid regions (1-5). A scrambled negative control was also designed to ensure that 
Spy1A knockdown was gene specific. Each shRNA sequence is flanked by HpaI and 
XhoI restriction sites to allow for direct subcloning into pLB (see Fig.5). Of the five 
Spy1A shRNA constructs designed, construct 2 has been subcloned into the pLB empty 
vector thus far. The degree to which shRNA constructs are expressed in a given cell 
population may be determined through GFP-fluorescence microscopy. Illustration of the 
highly conserved Speedy/RINGO box is provided on the Spy1A protein structure, and 
occupies amino acid positions 66 through 206. (Bottom) Forward (top strand) and reverse 
(bottom strand) sequences are listed for each Spy1A shRNA construct (5’-3’). Sense 
strands of each shRNA construct are highlighted in green; hairpin loop sequences are 
highlighted in red; antisense strands are highlighted in yellow. HpaI and XhoI restriction 
sites are highlighted in purple. 
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 reverse primer (A425):   
  5’-GCTCAGTAAACAACATGCATAAATCGAATTCTGGC-3’ 
SDM reactions contained the following components: Flag-Spy1A-pLXSN vector DNA 
(10-100 ng); 0.3 mM dNTP mix (Cat. No. DD0057, Biobasic Inc., Ontario, Canada); 1X 
pfx buffer and 1 ml pfx polymerase (Cat. No. 11708-013, Invitrogen, Canada); 1 mM 
MgSO4; 1 mM each of A424 forward and A425 reverse primers; filter-sterilized nuclease 
free water up to 50.0 ml. Cycling conditions for SDM included (1) 2 minutes at 94˚C, (2) 
25 cycles of 94˚C for 15 seconds, 55˚C for 30 seconds, and 68˚C for 5 seconds, and (3) 
68˚C for 10 minutes. DpnI digestion of SDM reaction products was performed for 2 h at 
37˚C as per manufacturer’s instructions (Cat. No. ER1701, Fermentas, Burlington, 
Ontario, Canada). DpnI digested products were transformed utilizing TOP10 E.coli and 
plated onto 100 mg/ml Ampicillin plates. Plasmid DNA was extracted from select 
colonies utilizing the QIAprep Spin Miniprep Kit (Cat. No. 27104, Qiagen, Mississauga, 
Ontario, Canada), and was EcoRI digested for 20 minutes at 37˚C (Cat. No. FD0274, 
Fermentas) as per manufacturer’s instructions. Colonies that produced a 977 bp fragment 
upon EcoRI digestion were sent for sequencing (Robarts Sequencing Facility, London, 
Ontario, Canada) utilizing sequencing primers A210 and A211: 
 forward primer (A210): 
  5’-CCCTTGAACCTCCTCGTTCGACC-3’ 
 
 reverse primer (A211):   
  5’-GAGCCTGGGGACTTTCCACACCC-3’ 
     Mutated to contain a second EcoRI site, Flag-Spy1A-pLXSN was EcoRI digested as 
per manufacturer’s instructions (Cat. No. ER0271, Fermentas). Digestion products were 
electrophoresed at 100V for 1 h, and the resultant 977 bp fragment was gel extracted 
utilizing the EZ-10 Spin Column DNA Gel Extraction Kit (Cat. No. BS354, Biobasic 
Inc.). MMTV-SV40-TRPS1 was EcoRI digested for 1 h at 37˚C, and incubated with calf 
intestinal alkaline phosphatase (Cat. No. EF0341, Fermentas) for 30 minutes at 37˚C as 
per manufacturer’s instructions. Reaction products were electrophoresed at 100V for 1 h, 
and the resultant 6.0 kb fragment was gel purified utilizing the EZ-10 Spin Column DNA 
Gel Extraction Kit. Vector ligation of gel extracts was performed as previously 
described,
63
 utilizing T4 DNA ligase (Cat. No. EL0017, Fermentas) as per manufacturer’s 
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instructions. Ligation products were transformed into TOP10 E. coli and plated onto 100 
mg/ml Ampicillin plates. Vector DNA was purified from select transformants and sent for  
sequencing (Robarts Sequencing Facility) utilizing the following four primer sets:  
  
 forward primer F1 (A252)   5'-GTTTTATCTGTGCTTATGCC-3' 
 reverse primer R1 (A253)   5'-GCTCGTATGTTGTGTGGAA-3' 
  
 forward primer F2 (A254)   5'-AACCATCACCCTAATCAAGT-3' 
 reverse primer R2 (A255)   5'-GTCGCCGCATACACTATT-3' 
 
 forward primer F3 (A256)   5'-TTATCCAGTCATACAGCAGG-3' 
 reverse primer R3 (A257)   5'-ACCCCTGCTGTATGACTGGA-3' 
 
 forward primer F4 (A258)   5'-GACCAGAATGTCCACCAGG-3' 
 reverse primer R4 (A259)   5'-GCCA CCTCTGACTTGAGCGT-3'. 
 
Successful clones were designated as MMTV-SV40-Spy1A, 30 mg of vector DNA was 
subjected to XhoI (Cat. No. ER0691) and SpeI (Cat. No. ER1251) double digestion as per 
manufacturer’s instructions (Fermentas), and was shipped to the London Transgenic and 
Gene Targeting Facility (London, Ontario, Canada) for blastocyst microinjection. 
 
III. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR).  
     Total RNA was extracted from cell pellets utilizing the GenElute
TM
 Mammalian Total 
RNA Miniprep Kit (Cat. No. RTN70-1KT, Sigma-Aldrich) or the RNeasy Plus Mini Kit 
(Cat. No. 74134, Qiagen) as per manufacturer’s instructions. RNA concentration and 
quality were determined via spectrophotometric analysis utilizing the NanoDrop ND-
1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). As per 
manufacturer’s instructions, SuperScript® II Reverse Transcriptase (Cat. No. 18064-014, 
Invitrogen) was utilized to convert up to 5 mg of total RNA to cDNA. Spectrophotometric 
analysis was utilized to determine the concentration and purity of resultant first-strand 
synthesis products. Human Spy1A and GAPDH forward and reverse primers were 
designed to recognize and amplify conserved exon-exon boundaries utilizing Primer 
Express 3.0 software:  
 forward Spy1A primer (A091)  5’-CCATGGGCTTTAGGGAAAAAC-3’ 
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 reverse Spy1A primer (A073)  5’-TGGCCATAACCTCCTCACAAC-3’ 
 forward GAPDH primer (A087)  5’-GCACCGTCAAGGCTGAGAAC-3’ 
 reverse GAPDH primer (A088)  5’-GGATCTCGCTCCTGGAAGATG-3’  
Primers were synthesized by Sigma-Genosys (Sigma-Aldrich). PCR reactions included 
the following components: a 1:1 dilution of first-strand reaction product (500-1000 ng); 
0.2 mM dNTP mix (Biobasic Inc.); 0.4 mM each of forward and reverse primers; 1X PCR 
buffer (Qiagen); 2.5 units/ml HotStar Taq DNA polymerase (Qiagen); filter-sterilized 
nuclease free water up to 50 ml. PCR cycling conditions included (1) denaturation at 94˚C 
for 3 minutes, (2) annealing at 94˚C for 1 minute, 55˚C for 2 minutes, and 72˚C for 1 
minute (N=25 cycles), and (3) elongation at 72˚C for 3 minutes. PCR products were 
separated on 8% polyacrylamide gel electrophoresis (PAGE) and imaged with GeneSnap 
software (SynGene) under UV fluorescence. 
 
IV. Cell Lines and Culture Conditions.  
     MCF7 cells were routinely subcultured in RPMI media (Cat. No. R8758, Sigma-
Aldrich) supplemented with 10% calf serum (CS, Cat. No. C8056, Sigma-Aldrich) and 
30,000 units penicillin/30,000 mg streptomycin solution (Cat. No. 15140-122, Invitrogen) 
and were maintained under normoxic conditions (5% CO2) at 37˚C. HC11 cells were 
provided as a kind gift by Dr. C. Shermanko, and were routinely subcultured in RPMI 
media supplemented with 10% calf serum, 30,000 units penicillin/30,000 mg streptomycin 
solution, 10 ng/ml insulin, 10 ng/ml epidermal growth factor (EGF), and 1 mM L-
glutamine, and were maintained under normoxic conditions (5% CO2) at 37˚C. 
     Isolation and routine subculture of MMTV-Myc tumor cell lines proceeded in the 
following manner. Mammary adenocarcinomas were freshly dissected from multiparous 
female F7 at 115 days (~16 wks). Similarly, virgin female F5A1 was derived from 
founder male F5 and developed aggressive mammary tumors that were subjected to fresh 
dissection 199 days (~28 wks) post-birth. Tumor tissue was directly placed in fresh, pre-
weighed collagenase buffer (10 mM Hepes, 2.5% FBS, RPMI 1640 supplemented with L-
glutamine) and subsequently weighed. In a sterile tissue culture hood, collagenase buffer 
and tumor tissue were poured together onto a 15 cm plate and chopped for 3 minutes, 
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using two 10-blade disposable scalpel blades bound together. Next, six razor blades were 
combined and utilized to break apart tumor tissue for an additional 10 minutes. At 5 
ml/gram tissue, fresh collagenase buffer was added to the tumor homogenate and 
supplemented with a final concentration of 1 mg/ml Sigma Blend L collagenase (Cat. No. 
C8176, Sigma-Aldrich). Incubation of the tumor homogenate ensued for 1 h at 37˚C 
during which the mixture was subjected to consistent shaking at 200 rpm. A second 
incubation period was initiated after addition of fresh 1mg/ml collagenase. The resultant 
mixture was pelleted at 1200 rpm in a refrigerated centrifuge for 10 minutes, followed by 
four 5 minute washes in collagenase buffer. All centrifugation spins were conducted at 
1200 rpm. Primary growth media (1X) was utilized to resuspend a purified cell pellet to a 
final volume of 20 ml, and the resultant cell suspension was seeded onto four 10 cm 
plates followed by routine cell culture. Primary tumor cell lines were designated as F7-1 
and F5A1-2, according to animal of origin and batch number. Cells were subcultured 
upon reaching 95% confluency. The subculture of cell lines required the removal of 
media, followed by 0.05% trypsinization (Cat. No. 25-052-CI, Mediatech, Inc., Manassas, 
VA, USA) for 2.5 minutes at 37˚C. Trypsinized cells were resuspended in 10 ml of fresh 
primary growth media (1X) and centrifuged for 5 minutes at 800 rpm. Resultant cell 
pellets were resuspended in 1 ml of fresh media and plated in a 1:50 ratio, followed by 
incubation at 37˚C under normoxic (5% CO2) conditions. Preparation of primary growth 
media (1X) required assembly of the following constituents: 500 ml DMEM-F12 media 
(Cat. No. D6421, Sigma-Aldrich) supplemented with 1 mM L-glutamine (Cat. No. 
G7513, Sigma-Aldrich); 5mg/ml insulin (Cat. No. I-6634, Sigma-Aldrich); 1mg/ml 
hydrocortisone (Cat. No. H0888-5G, Sigma-Aldrich); 10 ng/ml human EGF (Cat. No. 
13247-051, Invitrogen); 10% fetal bovine serum (Cat. No. F1051, Sigma-Aldrich); 
5ng/ml cholera toxin (Cat. No. C8052, Sigma-Aldrich); 100mg/ml penicillin/streptomycin 
(Cat. No. 15140-122, Invitrogen); 50 mg/ml gentamycin (Cat.No. 15710-064, Invitrogen). 
 
V. Assays for Transient Transfection and Stable Cell Line Production.  
     Twenty-four hours prior to transfection, cells were seeded at a 1:50 ratio on 10 cm 
plates in 7 ml of fully supplemented cell-specific media. As an alternative, cells may be 
29 
 
incubated in antibiotic/serum-free media in order to enhance DNA delivery, although this 
step is not required for successful transfection of F5A1-2 cells. Cells were transfected at 
40-50% confluency utilizing polyethylenimine (PEI) transfection reagent (Cat. No. 
408727, Sigma-Aldrich), prepared at a final concentration of 0.07 mg/ml in 750 ml media 
for each plate of cells. A nonviral polycationic polymer, PEI, was utilized for its efficient 
ability to complex to and deliver vector DNA to mammalian cell lines.
64
 Transfection 
assays were initially optimized for F5A1-2 primary cells by altering the PEI to DNA ratio 
and determining which concentration of GFP-tagged vector DNA (2 mg, 4 mg, 8 mg, 12 
mg, 20 mg) yielded the highest transfection rates. A concentration of 12 mg resulted in the 
greatest transfection efficiency. Therefore, 12 mg of plasmid DNA were added to each 
PEI-media mixture and vortexed for 30 s, followed by incubation at room temperature for 
5 minutes. PEI-DNA-media complexes were added directly to cells plated in 7 ml of fully 
supplemented media, gently rocked, and incubated at 37˚C under normoxia (5% C02) 
overnight. Media removal ensued 18-24 h post-transfection followed by downstream 
analysis. Transfection efficiency was assessed under GFP fluorescence microscopy, and 
was estimated to range from 20-30% at best in F5A1-2 cell lines.  
     PEI transfection of Lenti-X
TM
 293 producer cell lines (Cat. No. 632180, Clontech, 
Mountain View, CA, USA) was conducted in a similar manner, and was utilized to 
introduce control or Spy1A-shRNA vectors to a series of pre-optimized packaging 
vectors that code for the necessary viral components required to form lentiviral particles 
upon transduction of mammalian cell lines. Following production of infectious lentivirus, 
control and Spy1A knockdown particles were each concentrated and titered as previously 
outlined in Welm et al. (2008),
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 proceeded by infection of F5A1-2 primary tumor cell 
lines with respective shCntl or shSpy1A filter-sterilized viral preparations. Briefly, 2x10
5
 
F5A1-2 cells (passage P60) were plated per well (6-well plate) to determine the 
multiplicity of infection (MOI) value for late passage F5A1-2 primary cells. 50 ml, 100 
ml, or 250 ml of infectious shCntl lentiviral particles were utilized to transduce F5A1-2 
cells. Similarly, 50 ml, 150 ml, or 250 ml of infectious shSpy1A lentiviral particles were 
utilized to transduce F5A1-2 cells. ShCntl and shSpy1A lentiviral stocks utilized at 250 
ml per well (6-well plate) yielded the highest transduction levels in F5A1-2 cells (~40% 
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infection efficiency). Successfully infected shCntl and shSpy1A cell lines were 
determined through GFP-fluorescence microscopy. Subsequent culturing of each stable 
cell line ensued for an additional three passages, followed by preparation of frozen-down 
stable cell line stocks (stored in liquid nitrogen). Stock shCntl lentiviral particles 
contained a viral titre of 4x10
6
 transducing units (TU) per ml. Stock shSpy1A lentiviral 
particles contained a viral titre of 1x10
7
 TU per ml. The MOI value for F5A1-2 primary 
tumor cell lines was estimated at 5. Future preparation of early passage F5A1-2 stable cell 
lines, 20 ml of shCntl and 50 ml of shSpy1A lentiviral particles may be administered per 
well in order to infect a starting number of 1.6x10
4
 F5A1-2 cells per well (24-well plate). 
Lentiviral production and infection procedures have been separately described in further 
detail in the Appendix section.   
 
VI. Quantification of Cell Proliferation (Trypan Blue Exclusion).  
     As described above, control or Spy1A knockdown-treated cell suspensions were 
prepared 18-24 h post-transfection, and vortexed for 30 s prior to cell counting. Equal 
parts of trypan blue (Cat. No. T8154, Sigma-Aldrich) and cell suspension were combined 
(1:1 ratio), and differences in live cell number in response to treatment were quantified 
with the assistance of a haemocytometer under Brightfield microscopy. In total, an 
average of the number of live cells counted in each of four quadrants was calculated and 
applied to the following formula, in order to determine the total cell number present in 1 
ml of cell suspension: 
cells
/ml = (Average Cell Number) x (2 x 10
4
 
cells
/ml) 
All trials were completed in triplicate to impart statistical significance (N=3 replicates, 
p=0.0395, 1-tail distribution, unequal variance). 
 
VII. Morphological Analysis and Quantification.  
     F5A1-2 cells that scored positive for GFP were quantified utilizing the 20X 
magnification objective, and each 10 cm plate was examined for changes in cellular 
phenotype. Five morphologic categories were derived based on the following features: (1) 
round, (2) projected round, (3) spindle-like, (4) star-like or undefined, and (5) triangular. 
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Total cell number was quantified for each category and averaged over a total of three 
trials (N=3). Subsequently, averaged cell numbers for each category were converted to 
percentages in order to universally compare morphological changes from plate to plate, 
and also to account for plate variance in total number of positively transfected cells. 
Student’s t-test was utilized to determine whether percent differences in cell morphology 
were biologically significant. Results from quantification studies were verified by 
completing an additional three trials (N=3 replicates). The second set of replicates was 
conducted by screening a selected portion of each 10 cm plate held consistent between 
each treatment. Morphologic quantification and statistical analysis (Student’s t-test) were 
carried out as described above.   
 
VIII. Estradiol (E2) and MAPK Inhibition Treatments in MCF7 Cells.  
     Upon 80% confluency, MCF7 cells were incubated in 7 ml of phenol red-free RPMI 
media (Cat. No. 11835, Invitrogen) supplemented with dextran-coated charcoal (Cat. No. 
C6241, Sigma-Aldrich) stripped CS and 30,000 units penicillin/30,000 mg streptomycin 
solution for 2-3 days prior to treatment in order to remove endogenous effects of local 
hormone and growth factor signaling. On the day of treatment, cells were incubated with 
either dimethyl sulfoxide (DMSO, Cat. No. D4540, Sigma-Aldrich) or 50 ng/ml E2 (Cat. 
No. E1024, Sigma-Aldrich) for 2, 4, or 24 h, followed by cell harvesting for RNA or 
protein extraction at respective time points. Similarly, in a second set of experiments, 
MCF7 cells were incubated in phenol-red free, fully supplemented RPMI media for 2-3 
days. On the day of treatment, cells were incubated with either 10 mM SB202474 
(control) or 10 mM U0126 (MEK1/2) inhibitors for 1 h, followed by treatment with 50 
ng/ml E2 for 2 or 4 h, after which cell pellets were lysed for protein and analyzed through 
10% SDS-PAGE. E2 was initially prepared at a concentration of 10 mg/ml and serially 
diluted into 0.1 mg/ml and 50 ng/ml working solutions. The latter concentration was 
utilized for E2 treatment. SB202474 (Cat. No. 444180) and U0126 (Cat. No. 662005-
1MG) inhibitors were purchased from CalBiochem (San Diego, CA, USA), respectively 
and prepared as 10 mM stock solutions in DMSO.     
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IX. Antibodies.  
     Primary Antibodies: Rabbit polyclonal anti-Speedy/RINGO antibody (NB100-2521) 
was purchased from Novus Biologicals (Littleton, CO, USA). Rabbit anti-c-Myc antibody 
(C3956) was purchased from Sigma-Aldrich. Rabbit polyclonal anti-ERa (HC-20) (sc-
543); rabbit polyclonal anti-ERK2 (C-14) (sc-154); goat polyclonal anti-p-ERK1/2 (Thr 
202/Tyr 204) (sc-16982); rabbit polyclonal anti-p21 (C-19) (sc-397); goat polyclonal anti-
Cytokeratin 19 (CK19, N-13) (sc-33119); mouse monoclonal anti-Cytokeratin 18 (CK18, 
C-04) (sc-51582) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA). Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP™ 
Rabbit monoclonal antibody (#4370) was purchased from Cell Signaling (Danvers, MA, 
USA). Anti-p27
kip-1
 (Ab-2) Mouse monoclonal antibody (DCS72) (NA35) was purchased 
from CalBiochem. Mouse anti-Actin, Clone C4 (MAB1501R) was purchased from 
Millipore (Etobicoke, Ontario, Canada). Secondary Antibodies: Anti-Rabbit IgG (whole 
molecule)–Peroxidase antibody produced in goat (A0545) was purchased from Sigma-
Aldrich. Secondary goat antibody (sc-2020) was purchased from Santa Cruz 
Biotechnology, Inc. Anti-Mouse IgG (Fab specific)–Peroxidase antibody produced in 
goat (A9917) was purchased from Sigma-Aldrich. 
 
X. Protein Lysis and Immunoblotting Assays. 
     Homogenized tissue or cell pellets were re-suspended in appropriate volumes of 
protein extraction buffer and were subjected to cell lysis for 1 h at 4˚C with occasional 
vortexing. Tissue protein extraction buffer comprised the following ingredients: 50 mM 
Tris-HCl (Cat. No. T5941-1KG, Sigma-Aldrich), pH 7.4; 1.0% Nonidet P40 (Cat. No. 
5990-5, Caledon Laboratories LTD., Georgetown, Ontario, Canada); 0.25% sodium 
deoxycholate (Cat. No. BP349-100, FisherBiotech, Fair Lawn, NJ, USA); 1 mM EGTA 
(Cat. No. D0077, Biobasic Inc.), pH 8.0; 0.2% sodium dodecyl sulphate (Cat. No. L4509-
1KG, Sigma-Aldrich); 150 mM low salt sodium chloride (Cat. No. S-2830-1KG, ACP 
Chemicals Inc., Montreal, Quebec, Canada); 1.5% Antifoam Y-30 Emulsion (Cat. No. 
A6457-100ML, Sigma-Aldrich); nuclease-free water to a final volume of 10 ml. Cell 
protein extraction buffer entailed the following ingredients: 0.1% Nonidet P40; 20 mM 
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Tris (Cat. No. T-9235, ACP Chemicals Inc.), pH 7.5; 5 mM EDTA (Cat. No. 3460-1, 
Caledon Laboratories LTD.); and 0.1 mM sodium chloride. 1 ml of protein extraction 
buffer was supplemented with the following protease inhibitors: 5 mg/ml aprotinin (Cat. 
No. D0153-50MG, Biobasic Inc.); 5 mg/ml leupeptin (Cat. No. 103476-89-7, Biobasic 
Inc.); 5 mg/ml pepstatin A; 100 mg/ml PMSF (Cat. No. 52332, EMD Chemicals Inc., 
USA). Cell lysates were centrifuged for 10 minutes at 4000 rpm to pellet cellular debris, 
and protein supernatants were collected into a separate tube. A second 100-200 ml aliquot 
of each supernatant was prepared for protein quantification. The Bradford assay was 
utilized to create a standard curve of absorbance (595.0 nm) plotted against known BSA 
concentrations (0.3125 mg/ml, 0.625 mg/ml, 1.25 mg/ml, 2.5 mg/ml, and 5 mg/ml). 
Bradford reagent (B6916, Sigma-Aldrich) was added to 5 ml of protein sample to a final 
volume of 1 ml, and measured for absorbance at 595.0 nm. Protein samples (300 mg) 
were analyzed through 10% SDS-PAGE and membranes were blocked for 20 minutes in 
1% BSA (Cat. No. D0024, Biobasic, Inc.) followed by overnight incubation in primary 
antibody (4˚C). Primary antibodies were diluted in 1% BSA accordingly: 1:500 rabbit 
polyclonal anti-Spy1/RINGO; 1:1000 rabbit anti-c-Myc; 1:833 ERa; 1:833 total ERK2; 
1:833 phospho-ERK1/2 (Santa Cruz Biotechnology); 1:2000 phospho-ERK1/2 (Cell 
Signaling); 1:500 p21; 1:833 mouse p27; and 1:1000 actin. Membranes were washed 
three times for 2-3 minutes per wash in 0.5% Tween-20/TBS (TBST), followed by 1 h 
incubation in the corresponding secondary antibody prepared at a 1:5000 dilution. 
Membranes were washed three times for 2-3 minutes per wash in TBST, and imaged with 
AlphaEaseFC software under chemiluminescence (Alpha Innotech HD2 Gel 
Documentation System). Pierce* Enhanced Chemiluminescent Western Blotting 
Substrate (PI32106) was purchased from Thermo Fisher Scientific Co. (Ottawa, Ontario, 
Canada). 
 
XI. Mammary Fat Pad Transplants.  
     Please see the Appendix section for the impending protocol. Briefly, No. 4 inguinal 
mammary glands were cauterized to prevent endogenous stem cell populations from 
colonizing the mammary fat pad, which in turn served as an environmental substrate to 
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support transplanted stable cells of either type. Left cleared fat pads were injected with 
control shRNA stable cells, whereas right cleared fat pads were injected with Spy1A 
shRNA stable cells, unless otherwise stated.   
 
XII. Whole Mount Analysis.  
     Please see the Appendix section for the impending protocol. 
 
XIII. Transgenic MMTV-Myc Mouse Colony Propagation and Genotyping.  
     Three established MMTV-Myc (01XG2) breeder pairs were obtained as founders of 
our colony from the repository of Mouse Models of Human Cancer Consortium 
(MMHCC, Frederick, MD, USA). Each breeder pair was comprised of a hemizygous 
male or female, as well as a wild type FVB partner of female or male origin, depending 
on hemizygous gender. Three wild type breeder pairs of FVB mice were also purchased 
from Charles River Laboratory (Wilmington, MA, USA) to prevent inbreeding within the 
transgenic colony. Utilizing the optimized MMHCC guidelines outlined in Protocol 1: 
Allele: Tg(MMTV-Myc)3Led, all founder pairs were tail clipped and genotyped 
(http://mouse.ncifcrf.gov/available details.asp?ID=01XG2). Tail clips (0.5 cm) were 
processed utilizing the PureLink™ Genomic DNA Mini Kit (Cat. No. K1820-02, 
Invitrogen). Spectrophotometric analysis was utilized to determine the concentration of 
genomic DNA isolated from all tail clip samples. The following genotyping primers were 
utilized to amplify isolated genomic DNA:  
 forward primer (M022)  5'-CCCAAGGCTTAAGTAAGTTTTTGG-3'  
 reverse primer (M023)  5'-GGGCATAAGCACAGATAAAACACT-3'  
Primers were synthesized by Sigma-Genosys Canada (Sigma-Aldrich). Polymerase chain 
reaction (PCR) thermo-cycling resulted in the production of an 825 bp amplicon. Each 
PCR reaction consisted of 100 ng of purified genomic DNA; 0.2 mM dNTP mix; 0.5 mM 
each of M022 and M023 primers; 1X PCR buffer; 2.0 mM MgCl2; and 2.5 units/ml 
HotStar Taq DNA polymerase. PCR buffer, MgCl2, and HotStar Taq DNA polymerase 
were purchased from Qiagen (Cat. No. 203205). A final reaction volume of 50 ml was 
obtained using filter-sterilized nuclease free water. PCR cycling conditions included (1) 
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denaturation at 94˚C for 3 minutes, (2) annealing at 94˚C for 1 minute, 65˚C for 2 
minutes, and 72˚C for 1 minute (N=35 cycles), and (3) elongation at 72˚C for 3 minutes. 
PCR products were analyzed through 4.25% polyacrylamide gel electrophoresis (PAGE), 
and imaged with GeneSnap software (SynGene) under UV fluorescence. Two transgenic 
females (F7, F8) and one transgenic male (F5) were identified (Fig.6a) and could 
successfully transmit the MMTV-Myc transgene to offspring (Fig.6b). F5 and F7 animals 
were ear tagged (Cat. No. 1005-1, National Band and Tag Co., Newport, KY, USA). 
Subsequent breeding of hemizygous females with wild type mating partners led to 
development of aggressive mammary adenocarcinomas, and resulted in female sacrifice 
and tissue harvesting. Hence, hemizygous male F5 was utilized to derive the MMTV-Myc  
transgenic mouse colony for the duration of experiments. 
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Figure 6. Transgenic MMTV-Myc mouse colony propagation and genotyping. Tail clip 
samples derived from (a) MMTV-Myc female F7, and (b) Generation 1 MMTV-Myc 
offspring F1.1 and F1.2, were subjected to genomic DNA extraction, followed by PCR 
detection of the MMTV-Myc transgene. (a) l = molecular weight standard; +MMTV = a 
vector backbone known to contain the MMTV-LTR promoter served as a positive control 
for the successful detection of the 825 bp amplicon produced upon genotyping transgenic 
animals; +NEB = positive PCR control utilized to ensure that PCR conditions were in 
working order; Tnt = a negative primer control utilized to confirm the specificity of 
genotyping primers by excluding the transgene DNA template; F7.1.1 = 200 ng of F7 
genomic (g) DNA template utilized during PCR; F7.1.2 = 100 ng of F7 gDNA template; 
F7.1.3 = 50 ng of F7 gDNA template. (b) l = molecular weight standard; +MMTV = 
positive control that contains the transgene DNA template; Tnt = negative primer control; 
F1.1 = female offspring 1.1 probed positive for transgenic status; F2.1 = female offspring 
2.1 also probed positive for transgene status. 
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Results 
I. Creation of a Transgenic MMTV-Spy1A Mouse Model for In vivo Analysis of Spy1A 
Overexpression.  
     As previously described, Flag-Spy1A-pLXSN contains the complete coding sequence 
of the human Spy1A gene conjugated to a flag tag.
53
 SDM was utilized to create a second 
EcoRI site positioned near the terminal region of the human Spy1A coding sequence 
(Fig.7) in Flag-Spy1A-pLXSN for efficient removal of the intrinsic poly-A tail. SDM 
primers A424 and A425 were designed to flank the vector region targeted for mutation. 
SDM reaction products were DpnI digested, and subsequently transformed utilizing 
TOP10 E.coli and plated onto 100 mg/ml Ampicillin plates. Select colonies were screened 
for EcoRI insertion and were identified upon detection of a 977 bp fragment following 
EcoRI digestion of isolated plasmid DNA from each colony (Fig.8a). Successful EcoRI 
insertion was confirmed through sequencing for two colonies in particular, Is.1 and IIs.3, 
utilizing A210 and A211 sequencing primers. Purified vector DNA from Colony IIs.3 
was subjected to EcoRI digestion, and produced two fragments at 7.0 kb (vector 
backbone) and 1.0 kb (Spy1A gene insert). Digestion products were separated, and the 
appropriate 1.0 kb fragment was gel extracted and purified.  
     EcoRI digestion of 2 mg of MMTV-SV40-TRPS-1 vector DNA ensued, followed by 
the immediate removal of terminal phosphate groups from digested ends utilizing calf 
intestinal alkaline phosphatase. Phosphatase treatment was necessary in order to prevent 
the re-ligation of linearized vector DNA termini. Consequently, reaction products were 
separated, followed by gel purification of the resultant 6.0 kb fragment (MMTV-SV40 
backbone). Ligation of the Spy1A gene insert into the MMTV-SV40 backbone was 
conducted, and ligation reactions were subsequently transformed utilizing TOP10 E. coli 
and plated onto 100 mg/ml Ampicillin plates. Select colonies were screened for EcoRI 
insertion and were identified upon detection of a 977 bp fragment following EcoRI 
digestion of isolated plasmid DNA from each colony (Fig.8b). Successful cloning of the 
Spy1A coding sequence into the MMTV-SV40 vector backbone was confirmed through 
sequencing. Sequencing primers A252, A253, A254, A255, A256, A257, and A258 were 
utilized in order to verify the intactness of all transgenic vector components. 
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GAATTCGCGGCCGCGTCGACCTGCGACGGAGCCTTGACCGCCGTTGCCCGGCCCTCTCCC
GCGCAGCCCCGGGCTTCCGCAGGAATATTGGGAAACCAAAATGAGGCACAATCAGATGTG
TTGTGAGACACCACCTACTGTCACTGTTTATGTAAAATCAGGGTCAAATAGATCACATCA
GCCTAAAAAGCCCATTACTCTGAAGCGTCCTATTTGTAAAGATAATTGGCAAGCATTTGA
AAAAAATACACATAATAACAACAAATCTAAACGCCCCAAAGGACCTTGTCTGGTTATACA
GCGTCAGGATATGACTGCTTTCTTTAAATTATTTGATGACGATTTAATTCAAGATTTCTT
GTGGATGGACTGCTGCTGTAAAATTGCAGACAAGTATCTTTTGGCTATGACCTTTGTTTA
TTTCAAGAGGGCTAAATTTACTATAAGTGAGCATACCAGGATAAATTTCTTTATTGCTCT
GTATCTGGCTAATACAGTTGAAGAAGATGAAGAAGAAACCAAGTACGAAATTTTTCCATG
GGCTTTAGGGAAAAACTGGAGAAAATTGTTCCCTAATTTCTTAAAGTTAAGGGACCAGCT
CTGGGATAGAATTGACTATAGGGCTATTGTAAGCAGGCGATGTTGTGAGGAGGTTATGGC
CATTGCACCAACCCATTATATCTGGCAAAGAGAACGTTCTGTTCATCACAGTGGAGCTGT
CAGAAACTACAACAGAGATGAAGTTCAGCTGCCCCGGGGACCTAGTGCCACACCAGTAGA
TTGTTCACTCTGTGGTAAAAAAAGAAGATATGTTAGACTGGGATTGTCTTCATCATCATC
TTTATCCAGTCATACAGCAGGGGTGACAGAAAAACATTCTCAGGACTCATACAACTCACT
GTCAATGGACATAATAGGTGATCCTTCTCAAGCTTATACTGGTTCTGAAGGTATGATATA
GTAATA 
  C 
  ↑ 
TGCCAGAATTAGATTTATGCATGTTGTTTACTGAGCTCTAGTCAGTCCTTTCTGGCGGGG
ATACATAATAATTTATATACTCCAACAATATGAGTTAAATTAATCTTGAAACTTTCTCCC
CTTTCAGTTACTTTTTGTCTTGTGTCCATATTTGTTTTGTGGTGACCCACCTAAACAGAT
TTTTAATGTGACCTATGTTAAGTTGAAAACTAATGCACCATAAGCCTCAGTATTTTAAGA
GCCTGAATCATTTTTTTGAAATGTTTATTTTATTCAAAAGGGTTTCAAGAAGAAAATAAA
TTTACTTGTAATCTCAAAAAAAAAAAAAAAAAAAAAA 
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Figure 7. The coding sequence of the human Spy1A gene is targeted for mutation 
using SDM. SDM was utilized to create a second EcoRI site positioned near the terminal 
region of the human Spy1A coding sequence in flag-Spy1A-pLXSN for efficient removal 
of the intrinsic poly-A tail, since the MMTV-SV40-TRPS-1 vector already harbours a 
unique poly-A tail flanked by an SV-40 intron recommended for transgene expression. 
The flag-Spy1A-pLXSN vector contains a single EcoRI site at the beginning of the 
Spy1A coding sequence (highlighted in red, underlined). The mutated nucleotide falls 
within the second EcoRI insertion site and is highlighted in bold red to demonstrate the 
change (highlighted in red, underlined), thereby representing creation of a second EcoRI 
restriction site. The ATG start site is highlighted in blue (underlined). 
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     The resultant transgenic vector was designated as MMTV-SV40-Spy1A and contains 
an untranslated portion of the Ha-ras gene, in addition to an SV40 polyadenylation site.
66
 
Bacterial sequences such as those found in vector backbones have been noted to inhibit 
successful incorporation of transgenic DNA into the mouse blastocyst genome. Thus, 
XhoI/SpeI double digestion of purified vector DNA (30 mg per tube) ensued, and resulted 
in the production of two fragments: 4.7 kb (MMTV-SV40-Spy1A transgene) and 2.9 kb 
(remaining backbone). Two vials of XhoI/SpeI digested transgenic DNA were made 
available for microinjection into mouse blastocysts for subsequent creation of the first 
MMTV-SV40-Spy1A transgenic mouse model known to date (Fig.8c). Transgene 
detection of a single copy of MMTV-SV40-Spy1A DNA was tested utilizing the PCR 
conditions outlined for M022 and M023 genotyping primers (Fig.8d).  
 
II. Spy1A Elevation in c-Myc Overexpressing Mammary Tumors and Primary Tumor Cell 
Lines. 
     The polyoma middle T (PyT) oncogene lies upstream of both the c-Src/PI3K/Akt and 
Shc/Ras/MAPK pathways,
67
 whereas c-Myc is an established downstream target of 
MAPK signaling.
68 
For this reason, mammary tumor tissue derived from either MMTV-
Myc or MMTV-PyT transgenic mouse models (kindly provided by Dr. T. Seagroves) 
were utilized to determine the extent to which the endogenous expression profile of 
Spy1A varies in response to distinct tumorigenic hits in the mammary gland, particularly 
those associated with altered Raf/ERK kinase activity. Despite the involvement of MAPK 
signaling in both of these murine models, Spy1A elevation was unique only to c-Myc 
overexpressing mammary glands and tumor tissue (Fig.9) confirming Spy1A as a 
downstream target of c-Myc.
22
 Taken together, these data suggest that c-Myc induction of 
Spy1A may be mediated in part through Ras/Raf/ERK kinase signaling in vivo. Tissue 
localization in heterogeneous tumor samples is thought to account for the overall 
upregulation of p27 that occurs in concert with upregulated protein levels of Spy1A in 
MMTV-Myc mammary tissue (Fig.9), contrary to results obtained from in vitro Spy1A 
overexpression in myc-Spy1A inducible U2OS cells.
60
 Actin was implemented as a 
loading control for all data derived through immunoblotting. Next, to determine whether 
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Figure 8. Construction of the first MMTV-SV40-Spy1A transgenic mouse model. (a) 
SDM-derived mutant Flag-Spy1A-pLXSN constructs were identified upon detection of a 
977 bp fragment following EcoRI digestion of isolated plasmid DNA from each colony: 
colony 1.1 (lane 1); colony 1.2 (lane 2); colony 1.3 (lane 3); colony 2.1 (lane 4); colony 
2.2 (lane 5); and colony 2.3 (lane 6). The pLXSN vector backbone was estimated at 7.0 
kb, and the Spy1A insert was estimated at 1.0 kb (997 bp). (b) EcoRI digestion of the 
MMTV-SV40-Spy1A transgenic vector released the flag-Spy1A coding sequence from 
the remaining vector backbone. EcoRI digestion of the resultant transgene DNA produced 
a 977 bp fragment as expected, and confirmed successful cloning. The pMMTV-SV40 
backbone was estimated at 6.0 kb, and the flag-tagged Spy1A insert was estimated at 1.0 
kb (997 bp). (c) The MMTV-SV40-Spy1A vector was double digested with XhoI and 
SpeI to release the transgenic fragment from the remaining backbone. Digested vector 
DNA resulted in the production of two fragments: 4.7 kb (MMTV-SV40-Spy1A 
transgene) and 2.9 kb (remaining backbone). Two vials of Xho/SpeI digested transgene 
DNA were prepared for microinjection (lanes 1 and 2). (d) A single copy of MMTV-
SV40-Spy1A DNA can be detected utilizing PCR genotyping methods previously 
described in Materials and Methods. Transgene DNA was successfully detected using 8% 
PAGE, in order to verify the success of using the M022/M023 primer set for detection of 
the Spy1A transgene in tail clip samples. PCR amplification of MMTV-SV40-Spy1A 
vector DNA (lane 2) using M022/M023 primers produced an 825 bp amplicon, identical 
to the positive MMTV vector control (+ MMTV, lane 1) as expected. 
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Figure 9. The endogenous expression profile of Spy1A protein in c-Myc overexpressing 
mammary tumors. Fourth inguinal mammary tissue and tumors were isolated from wild-
type FVB, MMTV-Myc, and Polyoma Middle T Antigen (PyT) mouse models. Protein 
lysates were analyzed by 10% SDS-PAGE and probed with the indicated antibodies (sizes 
are included on the right in kilo Dalton (kD) units): non-transgenic control gland (Lac2); 
unaffected MMTV-Myc gland in transgenic animal (Myc Cntl); MMTV-Myc tumor in 
right gland (Myc 2R); MMTV-Myc tumor, gland not indicated (Myc T); PyMT 4154 
tumor in left gland (PyT 5L); PyMT 4153 tumor in right gland (PyT 1R+); wild-type 
FVB gland (FVB Cntl). The blot depicted here is one representative of N=2 replicates. 
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Spy1A elevation in c-Myc overexpressing tumors can be maintained during primary 
tumor culture, the MMTV-Myc mouse model, well documented for its ability to form 
aggressive mammary adenocarcinomas,
69
 was utilized to derive a previously 
uncharacterized tumor cell line engineered to overexpress c-Myc, henceforth referred to 
as F5A1-2. Fourth inguinal mammary glands were also extracted from wild-type FVB 
females, and utilized to determine whether c-Myc overexpression correlates with an 
increase in Spy1A expression in F5A1-2 cell lines. Thus, control glands represent a non-
tumorigenic equivalent of signaling within the breast micro-environment. Additionally, 
upregulation of c-Myc protein in primary tumor cells was confirmed through 
immunoblotting, correlating with a persistent elevation in Spy1A, whereas p27 levels 
remained virtually undetectable in comparison to control mammary gland tissue (N=3 
replicates, Fig.10). 
 
III. RNAi-Mediated Spy1A Knockdown in F5A1-2 Cell Lines Reduces Cell Proliferation 
and Alters c-Myc Levels In vitro.  
     To determine the essentiality of Spy1A for c-Myc induced tumorigenesis, F5A1-2 cell 
lines were transiently transfected with either shCntl or shSpy1A recombinant pLB 
vectors. Twenty-four hours post-transfection, alterations in cell proliferative capacity 
were quantified through trypan blue exclusion, demonstrating a statistically significant 
decrease in cell number upon short-term abrogation of Spy1A (Fig.11a). Knockdown of 
Spy1A was confirmed at the protein level through immunoblotting and appeared to 
downregulate c-Myc at earlier cell passages (~P35) when normalized to Actin (Fig.11b). 
Thus, under in vitro conditions, Spy1A has been implicated here as a potential mediator 
of tumor cell proliferation in mammary cells governed by enhanced c-Myc signaling.  
     In order to partially clarify the mechanism utilized by c-Myc to maintain a tumorigenic 
state in the mammary gland when the proto-oncogene is overexpressed, a subset of 
primary tumor cultures were independently infected with either control or Spy1A shRNA 
lentiviral particles for 24 h prior to removal of viral-containing media. Hereafter, resultant 
stable F5A1-2 cell lines will be referred to as F5A1-2
shCntl
 and F5A1-2
shSpy1A
, 
respectively. To allow for stable integration of each shRNA construct into the tumor cell 
genome, transduced cells were passaged three times (P3) and cell lines were subjected to  
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Figure 10. MMTV-Myc primary tumor cell lines continue to express elevated levels of 
Spy1A protein. F5A1-2 primary mammary tumor cell lines were derived from MMTV-
Myc transgenic mice (Myc OE-1, 2, 3). No. 4 inguinal mammary glands were extracted 
from wild-type FVB mice (FVB Cntl-1, 2, 3, 4) as an internal reference. Protein extracts 
were analyzed through 10% SDS-PAGE and probed with the indicated antibodies (sizes 
are included on the right in kilo Dalton (kD) units). The blot depicted here shows all 
replicates (N=4) for control fourth mammary gland tissue, in addition to displaying all 
replicates (N=3) for F5A1-2 whole cell extracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
immunoblotting in order to assess the efficacy of long-term Spy1A inhibition. In direct 
discordance with previous data (Fig.11b), immunoblotting revealed an upregulation of c-
Myc protein levels upon genetic silencing of Spy1A, together with an increase in 
phospho-ERK1/2 expression (Fig.12a). Note that overall changes in MAPK expression 
were calculated through densitometry by normalizing phosphorylated levels of ERK1/2 to 
those of total ERK1/2, whose basal protein expression remained consistent throughout all 
treatments (Fig.12b). Next, stable F5A1-2 cell lines were cultured for an additional two 
passages in preparation for upcoming mammary fat pad transplants. Analysis of protein 
expression via immunoblotting indicated insignificant Spy1A knockdown for either cell 
set, as evidenced by a 2% decrease (lanes 1-2, Cell Set No.1) and a 0.5% increase (lanes 
3-4, Cell Set No.2) in Spy1A protein expression, respectively (Fig.13a-b). Likewise, c-
Myc, ERK1/2, p21, and p27 protein levels did not fluctuate significantly for either cell set 
when compared to control knockdown treatments (Fig.13a-b). Thus, late passage F5A1-2 
cell lines appear to acquire resistance to RNAi-mediated Spy1A inhibition in response to 
long-term subculture. Note that densitometry values are considered to be preliminary at 
this stage of analysis due to inadequate statistical replication of data.   
 
IV. Transient Spy1A Knockdown May Alter Cellular Morphology In vitro. 
     Upon RNAi-mediated attenuation of Spy1A activity in P33 F5A1-2 cells, subtle 
morphological changes in cellular phenotype were consistently detected in comparison to 
control knockdown treatments. To discern the underlying reason for these alterations in 
phenotypic state, F5A1-2 cell lines were subjected to transient shRNA transfection for 24 
h and visualized through GFP-fluorescence microscopy. Morphological assessment of 
cell types could not be conducted under Brightfield microscopy, since transfection 
efficiencies never reached past 30%. A total of five morphological categories were 
chosen to represent the scope of phenotypic states available to each cell mass. These 
included round, projected round, spindle-like, undefined or star-like, and triangular 
(Fig.14). Only those cells successfully transfected and thus actively co-expressing GFP 
and either control or Spy1A shRNA were considered for the study. Green fluorescing 
cells were examined at a magnification of 20X and scored for their morphological 
appearance, followed by tallying the total number of cells that portrayed each phenotypic  
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Figure 11. Transient Spy1A knockdown affects cell proliferation rate and c-Myc 
protein levels in vitro. (a) Late passage F5A1-2 cell lines (>P60) were transfected with 
GFP-tagged Spy1A shRNA (shSpy1A) or scrambled shRNA (shCntl) recombinant 
constructs. Cells were counted 48-72 h post-transfection using trypan blue exclusion 
methods. Error bars indicate measurements of standard deviation calculated for N=3 
separate trials. *Student’s t-test was utilized to verify statistical significance where 
applicable (p=0.0395, 1-tail distribution, unequal variance). (b) Early passage F5A1-2 
whole protein extracts (P33) were assessed through 10% SDS-PAGE, followed by 
immunoblotting for c-Myc (67kD); Spy1A (36 kD); and Actin (43 kD). Actin was 
implemented as a suitable loading control; protein data were normalized to total levels of 
Actin. The blot depicted here is one representative of N=2 replicates. 
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Figure 12. Stable F5A1-2 cell lines exhibit differential signaling upon lentiviral-
mediated Spy1A knockdown. Primary cells cultured to passage 60 were stably infected 
with scrambled (shCntl) or Spy1A (shSpy1A) shRNA lentiviral particles for 72 h, after 
which stable knockdown cell lines were subcultured for an additional three passages (P3). 
(a) Protein lysates were extracted and subsequently analyzed through 10% SDS-PAGE, 
followed by immunoblotting with the indicated antibodies: c-Myc (67kD); CK18 (45 kD), 
a luminal epithelial cell marker; Spy1A (31 and 36 kD isoforms); phosphorylated ERK1/2 
(p-ERK 1/2) (42 and 44 kD isoforms); total ERK2 (ERK 2) (44 kD); and Actin (43 kD), 
utilized as a reliable loading control. The blot depicted here is representative of N=1 
replicate. (b) Densitometry was implemented in order to quantify pixel intensity for each 
protein band, and made use of Actin levels to normalize each data set. Resultant values 
were interpreted here as relative measures of protein expression for Actin (black); Spy1A 
(green); p-ERK/total ERK (blue); CK18 (tan); and c-Myc (purple). 
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Figure 13. Stable F5A1-2 primary tumor cell lines. Stable scrambled (shCntl) and 
Spy1A (shSpy1A) knockdown cell lines were subcultured over a total of five passages 
(P5) to a confluency of 90-95%, immediately after lentiviral infection. (a) Protein lysates 
freshly isolated from P5 stable cell lines were analyzed through 10% SDS-PAGE, and 
immunoblotted with the indicated antibodies: c-Myc (67kD); Spy1A (31 and 36 kD 
isoforms); phosphorylated ERK1/2 (p-ERK 1/2) (44 kD isoform); total ERK1/2 (ERK 2) 
(42 and 44 kD isoforms); p27 (27 kD); p21 (21 kD); and Actin (43 kD), a loading control. 
The blot depicted here depicts N=2 replicates of each F5A1-2 stable cell line. Cell set No. 
1 includes Cntl-1 (lane 1) and Spy1A-1 (lane 2) samples; cell set No. 2 includes Cntl-2 
(lane 3) and Spy1A-2 (lane 4) samples. (b) Normalized densitometry ratios measuring 
pixel intensity of each protein band were graphed for cell sets No. 1 (shCntl-1, shSpy1A-
1) and No. 2 (shCntl-2, shSpy1A-2): c-Myc (purple); Spy1A (green); p-ERK/total ERK 
(blue); p21 (fuschia); and p27 (orange). (c) Representative Brightfield (left panels) and 
GFP-fluorescence (middle panels) images were taken for shCntl and shSpy1A stable cell 
lines. An overlay of Brightfield and GFP-fluorescence images is also displayed (right 
panels), and provides an estimation of lentiviral infection efficiency. 
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state in a given 10 cm plate. Total cell counts for each morphological category were 
averaged against 3 replicates and converted to percentages based on total GFP-positive 
cell number (Fig.14a). Overall, the percentage of primary tumor cells exhibiting spindle-
like morphology increased significantly upon Spy1A knockdown (Fig.14a), whereas 
remaining phenotypic categories did not exhibit variations that were considered to be 
statistically significant, as evidenced by probability values greater than 5% (statistical p-
values not reported). It follows that an increase in the quantity of spindle-shaped F5A1-2 
tumor cells should correlate significantly with reduced cell types that exhibited 
round/projected round morphology at the time of analysis. However, a p-value of 0.054 – 
although marginal in statistical significance – demonstrated that this does not hold true. 
Therefore, to further clarify whether morphological changes resulted from a true change 
in cellular phenotype, rather than as a by-product of increased space within the tissue 
culture dish, and also to determine whether phenotypic changes were attributed to altered 
cell signaling, the protein status of CK18, a structural marker traditionally utilized to 
detect mammary cells of epithelial lineage,
70
 was assessed in mid passage (P33) F5A1-2 
cells differentially treated with shCntl or shSpy1A RNAi. Protein isolation ensued 24 h 
after shRNA treatment, followed by 10% SDS-PAGE analysis and immunoblotting for 
Spy1A, Actin, and CK18 (Fig.14c). Protein expression was subsequently quantified 
through densitometric analysis for both Spy1A and CK18 (data normalized to Actin). 
Following transient suppression of Spy1A gene activity (48%), CK18 protein levels 
decreased significantly by 31%, supporting that F5A1-2 cells respond to Spy1A inhibition 
by reverting to a myoepithelial-like cell state, in vitro. Immunoblotting ensued for a 
second luminal epithelial marker, CK19 to confirm CK18 results. However, since CK19 
protein expression was undetectable in both shCntl and shSpy1A treated cell lines (data 
not shown), acquisition of a myopepithelial cell fate remains to be verified.          
 
V. Estrogen Signaling Upregulates Spy1A mRNA and Protein Expression in MCF7 Cells. 
     ERa positive MCF7 cell lines are documented for their ability to respond to estradiol 
treatment with an increase in cell proliferative capacity.
12
 For this reason, MCF7 cells 
were utilized to determine the effects of estrogen signaling on Spy1A mRNA and protein  
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Figure 14. F5A1-2 tumor cell phenotype partially acquires spindle-like morphology 
upon abrogation of Spy1A signaling. F5A1-2 primary tumor cell lines were transfected 
with shCntl or shSpy1A recombinant pLB vectors. GFP-positive cells were counted under 
GFP fluorescence and were categorized into five morphological categories: round, 
projected round, spindle-like, undefined/star-like, and triangular. (a) Representative GFP-
fluorescence images appear above each cell type. Error bars indicate measurements of 
standard deviation as calculated for three separate trials. *Student’s t-test was utilized to 
verify statistical significance where applicable (p=0.02, Student’s t-test, 1-tail 
distribution, unequal variance; N=3 replicates). (b) Densitometry was conducted for the 
protein blot indicated in (c) for CK18, Actin, and Spy1A. Black bars are indicative of 
percent pixel intensity for Cntl shRNA samples; tan bars are indicative of percent pixel 
intensity for Spy1A shRNA samples (data normalized to Actin). (c) P33 F5A1-3 cell lines 
were subjected to protein extraction, followed by 10% SDS-PAGE and immunoblotting 
for the following antibodies: Spy1A (31 kD); CK18 (45 kD), an epithelial marker of 
luminal cell fate; and Actin (43 kD), utilized as a loading control. The blot depicted here 
is representative of N=1 replicate. 
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levels in vitro. The promiscuous behaviour of ERa and its ability to crosstalk and provide 
feedback to numerous signaling pathways during mammary development and 
tumorigenesis confounds the analysis of estrogen signaling alone.
71
 For this reason, media 
for estrogen receptor-positive MCF7 cells were charcoal-stripped of all endogenous 
hormone/growth factor signaling, and cells were treated for a period of 72 h or greater, 
prior to treatment with DMSO (vehicle control) or E2, a molecular derivative of estrogen. 
Administration of DMSO or E2 treatment for 2, 4, or 24 h preceded analysis through 
immunoblotting and RT-PCR. E2 increasingly stimulated Spy1A mRNA levels over a 24 
h time period, and effects of estrogen on Spy1A transcription were most prominent at 24 
h post-treatment (Fig.15a). Western blots confirmed the upregulation of Spy1A protein as 
early as 2 h post-treatment in response to E2 (Fig.15b), implicating Spy1A as a candidate 
downstream target for short-term estrogen signaling.    
 
VI. MAPK Mediates the Ability of Estrogen to Induce Spy1A Expression in MCF7 Cells. 
     Beyond MAPK-mediated transcriptional activation of ER, recent reports have 
indicated a heightened ability for E2 to stimulate ERK1/2 activity five minutes post-
administration in ER-positive cell types.
15
 In an effort to determine the underlying 
mechanism exploited by E2 to upregulate Spy1A in aberrantly proliferating mammary 
cells, we postulated that MAPK signaling plays a central role in E2-stimulated Spy1A 
expression. Although no study to date has evaluated the potential for MAPK members to 
directly elevate Spy1A, PD098059 inhibition of MEK1 activity produces in vitro 
downregulation of Spy1A in the immortalized HC11 cell system.
22
 Furthermore, 
Lenormand et al. (1999) previously established that Spy1A induction of Xenopus oocyte 
maturation is dependent upon intact MAPK signaling, and utilizing electromobility shift 
assays, demonstrated the capacity of exogenous Spy1A mRNA to trigger MAPK 
phosphorylation events in Xenopus oocytes as early as 2 h post-injection,
72
 suggesting the 
existence of a positive feedback loop between Spy1A and MAPK.  
     Therefore, in order to elucidate the degree to which E2 requires MAPK activation to 
induce Spy1A, I evaluated the ability of E2 to stimulate expression of Spy1A in MCF7 
cell lines subjected to short-term treatment with control (SB202474) or MEK1/2 (U0126)  
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Figure 15. Treatment with estradiol (E2) induces Spy1A mRNA and protein expression 
in MCF7 cells. MCF7 cells were incubated in phenol red free media supplemented with 
charcoal-stripped serum prior to treatment with E2 or DMSO. (a) Total RNA and (b) 
protein were extracted from cells undergoing treatment for 2, 4, or 24 h. (a) RT-PCR was 
performed (n=25 cycles) utilizing Spy1A and GAPDH specific primers. The blot depicted 
here is representative of N=1 replicate. Densitometry values for each mRNA band were 
normalized to GAPDH and converted to normalized mRNA expression (%). 2 h, 4 h, and 
24 h treatments (black bars). (b) Protein lysates were analyzed through 10% SDS-PAGE 
and probed with the indicated antibodies (sizes are included on the right in kilo Dalton 
(kD) units). The blot depicted here is one representative of N=2 replicates. Densitometry 
values for each protein band were normalized to Actin and converted to normalized 
protein expression (%). 2 h, 4 h, and 24 h treatments (black bars). 
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inhibitors. Following overnight incubation in phenol red free media containing charcoal-
stripped serum, MCF7 cells were treated chemically for 1 h with SB202474 or U0126 
inhibitors, followed by immediate administration of E2 for 2 h or 4 h. Isolation of protein 
ensued at respective time points, and protein lysates were analyzed through 10% SDS-
PAGE for ERa, c-Myc, Spy1A, phosphorylated and total levels of ERK1/2, in addition to 
the CKIs p21 and p27 (Fig.16a). Actin was implemented as a loading control due to its 
stable expression in mammary cells.
22
 Note that SB202474 and U0126 inhibitors were not 
removed prior to treatment with E2, allowing control and MEK1/2 inhibition to continue 
respectively throughout the entire time course. In this way, a total of 3 h of U0126 
treatment resulted in a 50% decrease in ERK1/2 protein expression as compared to 3 h of 
SB202474 control treatment (Fig.16b). Relative to 5 h of SB202474 control inhibition, 
MEK1/2 inhibition caused an 86% decline in ERK1/2 protein expression in response to 5 
h of U0126 treatment, further demonstrating that the potency of MAPK knockdown 
increases over longer treatment periods (Fig.16b). Interestingly, 2 h and 4 h of E2 
treatment following administration of MAPK inhibitory particles resulted in a respective 
decrease in total ERa levels by 20% and 27%, whose pattern of expression coordinated 
with the apparent decrease in p21 levels (16% and 35%, respectively) when compared to 
control inhibition (Fig.16b). Of key importance was a prominent decrease in Spy1A 
protein expression (43% and 91%, respectively) in response to 1 h of MAPK inhibition 
coupled to 2 h or 4 h of E2 stimulation when compared to control time points (Fig.16b). 
In contrast to previous reports,
73
 MAPK inhibition resulted in a 24% increase in c-Myc 
protein levels as early as 2 h post-E2 stimulation relative to control treatment, whereas the 
4 h time point did not invoke any significant changes in c-Myc expression (Fig.16b), as 
previously documented by Lobenhofer et al. (2000).
73
 Taken together, these data 
demonstrate that in vitro disruption of MAPK signaling reduces Spy1A protein levels in 
ERa-positive, estrogen-responsive BC cell lines, depending on the length of time cell 
populations are subjected to inhibitory exposure. Furthermore, results depicted here imply 
that E2 requires functional MAPK signal transduction to effectively upregulate Spy1A 
protein expression within the MCF7 cell system, although results are strictly preliminary 
and require additional replication to verify changes in protein expression. 
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Figure 16. Estradiol (E2) requires intact MAPK activation to induce Spy1A protein 
expression in the MCF7 cell system. MCF7 cells were incubated in phenol red free 
media supplemented with charcoal-stripped serum prior to 1 h treatment with control 
(SB202474) or MAPK (U0126) inhibitors. Following 1 h incubation with each inhibitor, 
E2 treatment ensued for 2 h or 4 h. (a) Total protein was extracted from cells undergoing 
E2 treatment for 2 h or 4 h, followed by analysis through 10% SDS-PAGE. Protein 
lysates were immunolabelled with the following antibodies: ERa (66kD); c-Myc (72 kD); 
Spy1A (31and 36 kD isoforms); phosphorylated ERK1/2 (p-ERK1/2) (42 and 44 kD 
isoforms); total ERK1/2 (42 and 44 kD isoforms); p21 (21 kD); and Actin (43 kD), the 
loading control. The protein blot depicted here is representative of N=1 replicate. (b) 
Densitometry values for each protein band were normalized to Actin and converted to 
normalized protein expression (%): ERa (red); c-Myc (purple); Spy1A (green); p-
ERK/total ERK (blue); and p21 (fuschia). 
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VII. Disrupted MAPK Signaling in the HC11 Cell System Results in Reproducible Spy1A 
Downregulation. 
     Since MAPK was shown to support Spy1A protein upregulation in an ERa-positive 
tumorigenic context (Fig.16a-b), I sought to further clarify the ability of MAPK signaling 
to precede Spy1A activation in a non-tumorigenic state. For this reason, the outcome of 
disrupted MAPK signaling on Spy1A expression was evaluated in the immortalized 
HC11 cell system, a p53
 
mutated mammary epithelial cell line that has been clonally 
derived from mid-pregnant BALB/c mammary epithelium.
74-75
 HC11 cells were exposed 
to 24 h treatment with either DMSO (vehicle control), 10 mM SB202474 (control), or 10 
mM PD098059 (MEK1) inhibitors. Protein isolation ensued, followed by immunoblotting 
for c-Myc, Spy1A, total and phosphorylated ERK1/2 levels, and the CKI p27 (Fig.17a). 
Actin was utilized as a loading control, and was further employed during densitometric 
analysis in order to normalize protein expression data. Utilizing SB202474 treatment as a 
baseline for protein expression, PD098059 inhibition of MEK1 activity by as little as 2% 
resulted in a 13% reduction in c-Myc, a 3% reduction in Spy1A, and an overall 2% 
increase in p27 protein levels (Fig. 17b). Overall, HC11 cells demonstrated inadequate 
MAPK inhibition in response to PD098059 exposure, and did not undergo significant 
changes in c-Myc, Spy1A, or p27 protein expression. Note that results have not been 
verified at this stage of analysis (N=1 replicate) and require additional replication in order 
to verify changes in protein expression.        
 
VIII. ERa-negative F5A1-2 Mammary Tumor Cells Harbour Intrinsic Defenses Against 
MAPK Inactivation. 
     Based on the importance of MAPK signaling for Spy1A stimulation in MCF7 cell 
lines subjected to long-term E2 exposure, MAPK was postulated to be indispensable for 
sustaining Spy1A upregulation in a c-Myc overexpressing tumor microenvironment. 
First, to resolve the extent to which F5A1-2 cells fall under ERa regulation, protein 
lysates isolated from F5A1-2 and MCF7 cell lines were subjected to 10% SDS-PAGE 
analysis and probed for ERa status. In relation to the naturally augmented protein levels 
of ERa pervasive in the MCF7 cell line, F5A1-2 cells were characterized accordingly as  
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Figure 17. Inhibition of MAPK activity downregulates Spy1A protein levels in the 
immortalized HC11 cell system. HC11 cells were treated independently for 24 h with 
either DMSO, 10 mM control inhibitor (SB202474), or 10 mM MAPK inhibitor 
(PD098059), followed by protein extraction and lysate analysis through 10% SDS-PAGE. 
(a) Protein lysates were immunoblotted utilizing the indicated antibodies: c-Myc (67 kD); 
Spy1A (36 kD isoform); phosphorylated ERK1/2 (p-ERK1/2); total ERK 2 (ERK 2); p27; 
and Actin (43 kD), utilized as a loading control. The blot depicted here is representative 
of N=1 replicate. (b) Densitometry values for each protein band were normalized to Actin 
and converted to normalized densitometry ratios: c-Myc (purple); Spy1A (green); p-ERK/ 
total ERK (blue); and p27 (orange). 
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ERa-negative (Fig.18). Thus, in a manner independent of ERa crosstalk, Myc-mediated 
upregulation of Spy1A is predicted to govern aberrant cell growth and irrepressible cell 
proliferation in those mammary adenocarcinomas derived from de novo overexpression of 
c-Myc.  
     Next, to determine the essentiality of MAPK for c-Myc induced stimulation of Spy1A 
in an ERa-negative context, F5A1-2 cells cultured beyond passage sixty were subjected 
to 24 h treatment with DMSO (vehicle control), 10 mM SB202474, 10 mM PD098059, or 
20 mM PD098059,  according to PD098059 concentrations pre-optimized by Lobenhofer 
et al. (2000) in the MCF7 cell system.
73
 Protein lysates were analyzed through 10% SDS-
PAGE, followed by antibody-mediated detection of Spy1A, phosphorylated ERK1/2, and 
total ERK1/2 levels (Fig.19a, Fig.20a). As determined through densitometric analysis, the 
ratio of phosphorylated ERK1/2 to total ERK1/2 was utilized as a method of quantifying 
changes in MAPK protein expression (Fig.19b, Fig. 20b). Relative to SB202474 
treatment, administration of PD098059 particles led to weak inactivation of MAPK by 
21% at 10 mM, and virtually no inactivation of MAPK (0.3%) at 20 mM concentrations 
(Fig.20a-b). Thus, optimal ERK1/2 inhibition was achieved at 10 mM. Downregulation of 
ERK1/2 by 21% corresponded to a 41% increase in Spy1A protein levels, in response to 
10 mM MAPK inhibition (Fig.20a-b). Similarly, negligible silencing of ERK1/2 (0.3%) 
produced a 5% increase in Spy1A protein expression, following 20 mM MAPK inhibition 
(Fig.20b). Collectively, these results demonstrate the ability of late passage F5A1-2 cells 
to evade the inhibitory effects of PD098059 within an ERa-negative tumorigenic context. 
Results, however, are strictly preliminary at this stage of analysis.    
     To determine the consequence of both MEK1 and MEK2 suppression on Spy1A-
associated signaling in F5A1-2 cell lines, SB202474 or U0126 inhibitor particles were 
utilized at 10 mM to treat passage 33 cells over a 24 h treatment period, followed by 
protein extraction and lysate analysis through 10% SDS-PAGE. Immunoblotting was 
utilized to assess deviations in protein expression for c-Myc, Spy1A, phosphorylated 
ERK1/2, and total ERK1/2, in addition to the cell cycle inhibitors p27 and p21 (Fig.19a). 
Densitometric analysis was subsequently utilized to quantify relative changes in protein 
expression, as determined through the normalization of data to Actin, the resident loading  
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Figure 18. ERa protein expression is absent in F5A1-2 cell lines. Protein extracts 
isolated from mid passage F5A1-2 (P33) and MCF7 (P30) cell lines were subjected to 
10% SDS-PAGE analysis and immunoblotted for ERa (66 kD) and Actin (43 kD), the 
loading control. The protein blot depicted here is representative of N=1 replicate. Lanes 
1-3: Mid passage F5A1-2 cell lines (P33) were treated independently for 24 h with 
DMSO (vehicle control), 10 mM control inhibitor (SB202474), or 10 mM MEK1/2 
inhibitor (U0126). l = protein standard.  Lanes 4-7: MCF7 cells were incubated in phenol 
red free media supplemented with charcoal-stripped serum prior to 1 h treatment with 
control (SB202474) or MAPK (U0126) inhibitors. Following 1 h incubation with each 
inhibitor, E2 treatment ensued for 2 h or 4 h. 
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control (Fig.19b). Whereas U0126 treatment (10 mM) effectively reduced ERK1/2 protein 
expression in MCF7 cell cultures (Fig.16), F5A1-2 cells remained impervious to inhibitor 
effects, as evidenced by stable ERK1/2 expression across all treatments (Fig.19). Despite 
the inability of U0126 to inhibit MAPK signaling in F5A1-2 cells, Spy1A protein levels 
increased by 12% relative to control treatments, whereas c-Myc, p21, and p27 levels were 
largely unaffected (Fig.19b). Furthermore, the ability of PD098059 to reduce ERK1/2 
protein expression was approximately 46-fold superior to that of U0126 when utilized at a 
final concentration of 10 mM in F5A1-2 cell cultures. Conversely, analogous experiments 
conducted in MCF7 cells identified U0126 as a more potent inhibitor of MAPK signaling 
in comparison to PD098059.
73
 Taken together, these data reveal an interesting property of 
F5A1-2 cell lines, i.e. their ability to circumvent MAPK inhibition when exposed to well 
characterized MEK inhibitors.  
        
IX. Establishing a Tumor Baseline for F5A1-2 Cells in Cleared No. 4 Mammary Glands 
of FVB Females.  
     To determine whether FVB-derived F5A1-2 cell lines retained their potential to form 
tumors in vivo, the rate of F5A1-2 tumor development was established in 24-day old FVB 
females via mammary fat pad transplantation, coupled to subsequent monitoring of tumor 
growth. Mammary fat pad removal primed each No. 4 inguinal mammary gland for 
injection with (a) saline solution (left gland), or (b) F5A1-2 cell suspension (right gland) 
at a dosage of 1x10
6
 cells per gland. Tumor nodules localized to the right-hand side first 
appeared 5 days post-surgery in all replicates tested, as detected through daily palpitation 
of recuperating No. 4 mammary glands. The absence of tumor formation on the left-hand 
side was confirmed through post-mortem dissection of each test subject. Representative 
autopsy images have been provided for test subject No.97, whose untimely death 
transpired 20 days post-surgery (Fig.21a). Serving as a general indicator for overall tumor 
size, calliper measurements of tumor height (depicted in Fig.21b) were reported for living 
test subjects on post-surgery days 5, 19-21, 24-26, 28, and 30-31 (Fig.21c). To determine 
the rate of F5A1-2 mediated tumor growth in transplanted FVB test subjects, linear 
regression analysis {y = (0.8 
mm
/day)(x) – 2.8 mm} for average tumor height (y) plotted  
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Figure 19. F5A1-2 primary tumor cell lines overexpressing c-Myc are resilient to 
chemical-mediated MAPK inhibition. Mid passage F5A1-2 cell lines (P33) were treated 
independently for 24 h with DMSO (vehicle control), 10 mM control inhibitor 
(SB202474), or 10 mM MEK1/2 inhibitor (U0126). Protein lysates were prepared after 
each treatment and analyzed through 10% SDS-PAGE, followed by immunoblotting. The 
protein blot depicted here is representative of N=1 replicate. (a) Protein lysates were 
immunolabelled with the following antibodies: c-Myc (72 kD); Spy1A (31 and 36 kD 
isoforms); phosphorylated ERK1/2 (p-ERK1/2) (42 and 44 kD isoforms); total ERK 1/2 
(ERK 1/2) (42 and 44 kD isoforms); p27 (27 kD); p21 (21 kD); and Actin (43 kD), 
utilized as a loading control. (b) Densitometry values for each protein band were 
normalized to Actin and converted to normalized protein expression (%): Spy1A (green); 
p27 (orange); c-Myc (purple); p21 (fuschia); and p-ERK/total ERK (blue). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
A 
 
PD098059
DMSO Cntl 10 mM 20 mM
IB: Spy1A
36 kD
31 kD
IB: p-ERK1/2
44 kD
42 kD
IB: ERK1/2
44 kD
42 kD
 
 
 
 
B 
 
     
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1 2 3 4
Spy1A
p-ERK/total ERK
total ERK1/2
N
o
rm
a
li
z
e
d
 D
e
n
s
it
o
m
e
tr
y
 R
a
ti
o
DMSO Cntl 10 mM 20 mM
PD098059
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
Figure 20. Primary tumor cell lines overexpressing c-Myc are resilient to chemical-
mediated MAPK inhibition. Primary tumor cell lines cultured beyond passage 60 (~P60) 
were treated independently for 24 h with DMSO, 10 mM control inhibitor (SB202474), 10 
mM MAPK inhibitor (PD098059), or 20 mM PD098059. Protein lysates were prepared 
after each treatment and analyzed via 10% SDS-PAGE. The protein blot depicted here is 
representative of N=1 replicate. (a) Protein lysates were immunolabelled with the 
following antibodies: Spy1A (31 and 36 kD isoforms); phosphorylated ERK1/2 (p-
ERK1/2) (42 and 44 kD isoforms); and total ERK 1/2 (ERK 1/2) (42 and 44 kD 
isoforms), utilized here as the loading control. (b) Densitometry values for each protein 
band were normalized to total ERK, and converted to normalized densitometry ratios: 
Spy1A (green); p-ERK/total ERK (light blue); and total ERK (dark blue). 
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against the number of days post-surgery (x) was subsequently conducted. Thus, tumor 
development progressed at an estimated rate of 0.8 mm per day. The linear relationship 
established between average tumor size and passage of time was significantly strong, as 
evidenced by a correlation coefficient (r) of 0.97 (Fig.21c). Only test subject No.99 
survived to day 31 post-surgery, exhibiting a final tumor height that exceeded 25.0 mm in 
length (Fig.21b-c). Due to enlarged tumor growth, humane sacrifice was conducted. Note 
that all error bars displayed in Fig.21c represent standard error values that have been 
calculated separately for each time point. 
 
X. Transient RNAi-Mediated Inhibition of Spy1A Slightly Reduces F5A1-2 Tumor Growth 
Rate In vivo.  
     To assess the essentiality of Spy1A for c-Myc induced tumor proliferation in vivo, 
F5A1-2 cells were transiently transfected for 24 h with either control or Spy1A shRNA 
vectors, followed by transplantation into the cleared fat pads of fourth inguinal mammary 
glands residing in 24-day old FVB females. Once again, mammary fat pad removal 
prepared each fourth gland for injection with (a) saline solution (left gland), or (b) control 
shRNA-treated F5A1-2 cell suspension (right gland) at a dosage of 1x10
6
 cells per gland. 
A second set of transplants was conducted in parallel to the first via injection of (a) saline 
solution (left gland), or (b) Spy1A shRNA-treated F5A1-2 cell suspension (right gland) at 
a dosage of 1x10
6
 cells per gland. Similar to the tumor baseline established for untreated 
F5A1-2 cells, tumor activity was initially observed ~7 days post-surgery and was 
restricted to the right-hand side in both control and Spy1A-shRNA treated animals, as 
determined through daily palpitation of each mammary gland. In addition to both shRNA 
transplant models described above, transplantation of one animal was conducted in the 
following manner to confirm the sterility of the saline solution, and to ensure proper 
clearing of the mammary fat pad: (a) un-cleared left gland, and (b) saline injected, cleared 
right gland (Fig.22a). Dissection of control (Fig.22b) and Spy1A (Fig.22c) shRNA- 
treated animals ensued at various time points, and at first glance, did not display 
significant variances in gross tumor size between treatments. Consequently, calliper 
measurements of tumor height were utilized as indicators of overall tumor size for both 
transplantation sets, and were reported for living test subjects on post-surgery days 23-24,  
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Figure 21. Tumor baseline for F5A1-2 cells. Cleared No. 4 inguinal mammary glands 
were transplanted with saline solution (left gland, L), or F5A1-2 cell suspension (right 
gland, R) at a dosage of 1x10
6
 cells per gland (N=6 replicates). (a) Autopsy photograph of 
test subject No.97, 20 days post-surgery. The highlighted region depicts extensive tumor 
growth in the R gland, compared to no tumor growth in the L gland. (b) Autopsy 
photograph of test subject No.99, 31 days post-surgery. As depicted in region , tumor 
height (mm) was measured daily for each test organism utilizing a Vernier Calliper, and 
represents overall tumor size at each time point. (c) Calliper measurements of tumor 
height were recorded for living test subjects on post-surgery days 5, 19-21, 24-26, 28, and 
30-31. The rate of tumor growth was determined through linear regression analysis for 
average tumor height (y) plotted against the number of days post-surgery (x) utilizing 
Microsoft Excel. The slope of the corresponding linear equation was utilized to determine 
the overall rate at which tumors develop from F5A1-2 cells: {y = (0.7967 
mm
/day)(x) – 
2.8489 mm}; slope = 0.7967 
mm
/day. Error bars indicate the standard error value for each 
time point. The correlation coefficient (r) was determined by calculating the square root 
of R
2
, a value derived through Microsoft Excel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
80 
 
and 27-29 (Fig.22d). Linear regression analysis was utilized once again to mathematically 
model differences in tumor growth rate between control and Spy1A treatments of F5A1-2 
transplanted cells (Fig.22d). Derived by plotting average tumor height (y) against the 
number of days post-surgery (x), the following linear equations were utilized to quantify 
the rate of tumor formation for control {y = (1.4 
mm
/day)(x) – 25.3 mm} and Spy1A {y = 
(1.3 
mm
/day)(x) – 22.9 mm} shRNA treated animals. Thus, tumor development in Spy1A 
shRNA-treated F5A1-2 cells proceeded at a slightly reduced rate of 1.3 mm per day, in 
comparison to control transplants estimated to expand by a rate of 1.4 mm per day (Fig. 
22d). Substantiated by r values of 0.92 and 0.97 respectively, both linear relationships 
established between average tumor size and passage of time for control and Spy1A 
shRNA treated cells were sufficiently strong (Fig.22d). As calculated for the F5A1-2 
tumor baseline, error bars displayed in Fig.22d represent standard error values that have 
been derived independently for each time point.      
      
XI. Transient Spy1A Knockdown in F5A1-2 Cells Potentiates the Development of Ductal 
Outgrowths In vivo.   
     The natural preponderance of Spy1A mRNA and protein expression in adult virgin 
mammary glands was postulated to promote typical ductal morphogenesis in vivo, 
especially since Spy1A overexpression in HC11 cells gives rise to premature lobular 
development when transplanted into 22-day old syngeneic BALB/c mice.
22
 First, to 
resolve the effects of F5A1-2 tumorigenicity on terminal end bud development during 
early stages of murine pubescence, mammary glands previously injected with saline 
solution or control shRNA-treated F5A1-2 cells (as described above) were isolated 11 
days post-surgery, followed by whole mount analysis through haematoxylin staining 
(Fig.23a). Although F5A1-2 transplantation did not completely abolish ductal 
morphogenesis, ductal side branching in the right gland was considerably reduced in 
relation to the left gland (Fig.23a), demonstrating the potent ability of F5A1-2 tumor cells 
to interfere with terminal end bud formation during post-natal mammopoiesis. Next, to 
determine whether RNAi-mediated Spy1A inhibition in F5A1-2 cells restores ductal side 
branching in vivo, fourth inguinal mammary fat pads were cleared in pre-pubertal FVB 
females, followed by transplantation of wild-type F5A1-2 cells (left gland) or shSpy1A- 
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Figure 22. Transient Spy1A knockdown reduces F5A1-2 tumor growth rate in vivo. 
Cleared No. 4 inguinal mammary glands were transplanted with saline solution (left 
gland, L), or control shRNA-treated F5A1-2 cell suspension (right gland, R) at a dosage 
of 1x10
6
 cells per gland (N=15 replicates). In parallel to the first set of surgeries, a second 
set was conducted via injection of saline solution (L), or Spy1A shRNA-treated F5A1-2 
cell suspension (R) at a dosage of 1x10
6
 cells per gland (N=15 replicates), unless 
otherwise stated. (a) Autopsy photograph of test subject No.120, 52 days post-surgery 
(N=1 replicate); No.120 was utilized as a control animal during mammary fat pad 
transplantation to ensure proper technique and clearing of the mammary fat pad. No. 4 
inguinal mammary glands were not cleared (no treatment, L) or injected with 10 ml saline 
solution (1X PBS). Region  points to an untouched fourth mammary gland. 
Region demonstrates successfully clearing of the fat pad, depicted by a lack of growth 
in the R fourth mammary gland region; therefore, proper clearing ensured full removal of 
stem cell precursors residing in pre-pubertal mice (21-28 days old) prior to transplantation 
of treated cell types. (b) Autopsy photograph of test subject No.116, 34 days post-
surgery. Region  points to the development of large shCntl F5A1-2 tumor masses in the 
R gland; F5A1-2 tumor cells have also invaded into the contralateral L gland (one 
replicate of 15). (c) Autopsy photograph of test subject No.111, 38 days post-surgery. 
Region  points to the development of large shSpy1A F5A1-2 tumor masses in the R 
gland; F5A1-2 tumor cells have once again invaded into the contralateral L gland (one 
replicate of 15). (d) Calliper measurements of tumor height were recorded for living test 
subjects on post-surgery days 23-24 and 27-29. The rate of shCntl tumor growth was 
determined through linear regression analysis for average tumor height (y) plotted against 
the number of days post-surgery (x) utilizing Microsoft Excel. The slope of the 
corresponding linear equation was utilized to determine the overall rate at which tumors 
develop from shCntl transfected F5A1-2 cells: {y = (1.4018 
mm
/day)(x) – 25.271 mm}; 
slope = 1.4018 
mm
/day. Similarly, the rate of shSpy1A tumor growth was determined 
through linear regression analysis for average tumor height (y) plotted against the number 
of days post-surgery (x) utilizing Microsoft Excel. The slope of the corresponding linear 
equation was utilized to determine the overall rate at which tumors develop from 
shSpy1A transfected F5A1-2 cells: {y = (1.2509 
mm
/day)(x) – 22.907 mm}; slope = 1.2509 
mm
/day. Error bars indicate the standard error value for each time point. The correlation 
coefficient was determined by calculating the square root of R
2
, a value derived through 
Microsoft Excel.     
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treated F5A1-2 cells (right gland). Test subjects were sacrificed 7 days post-surgery in 
preparation for whole mount analysis through haematoxylin staining (Fig.23b-c). 
Emanating directly from transplanted cells, the number of pronounced ductal side 
branches residing in right glands was markedly increased when compared to 
corresponding left glands (Fig.23b-c). Instead, left whole mounts were populated mostly 
by massive tumor structures, as evidenced by profuse purple staining dispersed 
throughout the tissue (Fig.23b-c). Residual cell suspensions frozen down directly after 
surgery were analyzed through 10% SDS-PAGE and immunoblotted for Spy1A, c-Myc, 
and Actin expression (data not shown). Spy1A and c-Myc levels were respectively 
reduced by 19% and 20% in shSpy1A-treated lysates compared to control lysates, thereby 
confirming Spy1A knockdown in No. SH01 (Fig.23b) and No. SH04 (Fig.23c) right 
glands, and further suggesting that Spy1A knockdown in F5A1-2 cells potentiates ductal 
morphogenesis in vivo. Taken together, whole mount data suggest that downregulation of 
Spy1A in F5A1-2 cells appears to partially restore ductal morphogenesis in vivo, although 
additional replicates are required to fully substantiate the statistical significance of whole 
mount data.   
 
XII. Transient Abrogation of Spy1A Signaling Downregulates c-Myc and MAPK Protein 
Expression In vivo. 
      To account for biological variation in different animals and to verify that Spy1A 
knockdown reduces F5A1-2 tumor formation in vivo within the same organism, 
mammary fat pad transplants were repeated in 24-day old FVB females as described 
previously, utilizing the following schema: (a) control shRNA-treated F5A1-2 cell 
suspension (left gland) at a dosage of 1x10
6
 cells per gland, and (b) Spy1A shRNA-
treated F5A1-2 cell suspension (right gland) at a dosage of 1x10
6
 cells per gland. Test 
subjects were sacrificed and freshly dissected 30 days post-surgery, following 
development of conglomerated tumor masses within the fourth inguinal mammary region. 
Autopsy images did not reveal significant changes in overall tumor size between control 
and Spy1A shRNA treatments due to F5A1-2 cell ability to invade into neighbouring 
tissues early on. Hence, successful separation of left and right tumors from one another 
was not feasible in those animals that were co-injected with control and Spy1A shRNA- 
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Figure 23. Transient Spy1A knockdown in F5A1-2 cells promotes ductal outgrowth 
development and ductal bifurcation in vivo. Representative regions of ductal outgrowth 
and bifurcation are indicated by a series of black arrows (→). The site of the lymph node 
(LN) has been demarcated for each whole mount, and serves as a positional frame of 
reference. (a) Mammary fat pad transplants were conducted in 28-day old FVB females. 
Cleared No. 4 inguinal mammary glands were transplanted with saline solution (left 
gland, L), or control shRNA-treated F5A1-2 cell suspension (right gland, R) at a dosage 
of 1x10
6
 cells per gland (N=15 replicates) for test subject No. 180. L and R fourth glands 
were extracted from No.180, 11 days post-surgery, and stained with haematoxylin during 
the whole mount procedure. (b-c) Mammary fat pad transplants were performed in 23-
day old FVB females. Fourth glands were cleared and transplanted with wild-type F5A1-
2 cells (L) or shSpy1A-treated F5A1-2 cells (R). Test subjects SH01 and SH04 were 
sacrificed 7 days post-surgery in preparation for whole mount analysis through 
haematoxylin staining (N=2 replicates), and were pair-matched for age. (b) L and R whole 
mount glands of SH01. The boxed region represents an enlarged view of select mammary 
ductal outgrowths that have sprouted from the site of cell injection. (c) L and R whole 
mount glands of SH04. The boxed region represents an enlarged view of select mammary 
ductal outgrowths that have sprouted from the site of cell injection.   
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treated cells, due to an evident lack of tumor boundary. Although calliper measurements 
of tumor height were recorded regularly at various time intervals after surgery, 
differences in tumor growth rate could not be assessed accurately within the same 
organism. Taken together, these results confirm the necessity of performing 
individualized transplants in separate test organisms for either control or Spy1A shRNA 
treated F5A1-2 cells (as performed above), due to their highly proliferative and invasive 
nature in vivo.  
     In an effort to elucidate the in vivo consequences of Spy1A knockdown on MAPK, c-
Myc, and CKI signaling, tumors harvested 30 days after surgery were analyzed for altered 
protein expression. Tissue samples were extracted from the periphery of both left and 
right tumor masses, since the tumor centre was speculated to contain a heterogeneous 
population of control and Spy1A RNAi-treated cells. Tissue homogenization and protein 
isolation ensued shortly thereafter for test subjects No.106 and 107, followed by 10% 
SDS-PAGE analysis and immunoblotting for c-Myc, Spy1A, phosphorylated and total 
ERK1/2, in addition to p27 (Fig.24a). Densitometric analysis (Fig.24b) was utilized to 
quantify changes in protein expression, during which pixel intensity of each protein band 
was determined and normalized to Actin, the resident loading control. Spy1A expression 
was effectively silenced in tumor samples excised from the right glands of test subjects 
No.106 and 107 by 52% and 31%, respectively, as compared to corresponding control 
tumor samples extracted from each left gland (Fig.24b). Spy1A knockdown resulted in c-
Myc downregulation by 55% and 53%, respectively, relative to control tissue (Fig.24b). 
In response to Spy1A inhibition, overall phospho-ERK1/2 protein expression decreased 
substantially in test subject No.106, as evidenced by a 73% decrease in the ratio of p-
ERK1/2 to total ERK1/2 (Fig.24b). Similarly, test subject No.107 experienced a 52% 
decline in overall phospho-ERK1/2 expression in tumor tissue derived from the right 
gland, as compared to control tissue extracted from the left (Fig.24b). Furthermore, a 52% 
decrease in Spy1A expression corresponded to a 71% decrease in p27 (No.106), whereas 
p27 expression was upregulated by 39% in response to 31% Spy1A inhibition when 
compared to control tissue (No.107). Results are prospectively confounded, however, by 
the insufficient separation of shCntl and shSpy1A tumor populations from one another in 
each tissue sample, and additional replicates are required to impart statistical significance. 
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Figure 24. Transient abrogation of Spy1A signaling downregulates c-Myc expression 
in vivo. No. 4 inguinal mammary glands of 24-day old FVB females were cleared and 
transplanted with control shRNA-treated F5A1-2 cell suspension (left gland, L) at a 
dosage of 1x10
6
 cells per gland, and Spy1A shRNA-treated F5A1-2 cell suspension (right 
gland, R) at a dosage of 1x10
6
 cells per gland (N=7 replicates). Test subjects were 
sacrificed and freshly dissected 30 days post-surgery. Tumor growth rate could not be 
determined accurately in animals co-transplanted with shCntl and shSpy1A F5A1-2 cells 
for this round of fat pad transplants. (a) Whole tumor protein extracts were isolated from 
the periphery of L and R tumor tissues to avoid the mixed tumor population located in the 
centre of the organism. Protein analysis was conducted through 10% SDS-PAGE for L 
and R tumors (T) isolated from No.106 and 107 animals (N=2 replicates, in total). 
Immunoblotting ensued for c-Myc (67 kD); Spy1A (36 kD); phosphorylated ERK1/2 (42 
kD); total ERK1/2 (42 kD); p27 (27 kD); and Actin (43 kD), the resident loading control. 
(b) Densitometric analysis was completed for the immunoblot depicted in (a); all protein 
data were subsequently normalized to total Actin expression and converted to normalized 
densitometry percentages (%). Spy1A (green); c-Myc (purple); p-ERK/total ERK ratio 
(blue); p27 (orange).       
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XIII. Stable Spy1A Knockdown In Late Passage F5A1-2 Cells Confirms Reduction of c-
Myc and MAPK Protein Levels In vivo.  
     Though PEI-mediated transfection is ideal for immediate assessment of foreign gene 
expression in a plethora of in vitro cell-based systems,
 
its benefits are typically short-
lived. Transient transfection does not stably integrate foreign DNA into the cellular 
genome and produces a partial or complete loss of foreign gene expression with every 
new mitotic cell division.
76-78
 Alternatively, lentiviral transduction circumvents these 
issues quite effectively and for this reason, F5A1-2
shCntl
 and F5A1-2
shSpy1A
 stable cell lines 
were transplanted into pre-pubertal No. 4 inguinal mammary glands of FVB females 
according to the following schema: (a) F5A1-2
shCntl
 cell suspension (left) at a dosage of 
1x10
6
 cells per gland, and (b) F5A1-2
shSpy1A
 cell suspension (right) at a dosage of 1x10
6
 
cells per gland (Fig.25a-e). Determined through GFP-fluorescence microscopy, lentiviral 
infection efficiencies were originally estimated to be 25-30% for F5A1-2
shCntl
 cells, and 
40-50% for F5A1-2
shSpy1A
 cells (Fig.13c). Cell suspensions derived from F5A1-2
shCntl
 and 
F5A1-2
shSpy1A
 treatments were utilized to determine the efficacy of Spy1A knockdown in 
F5A1-2 stable cell lines prior to in vivo mammary fat pad transplantation, as determined 
through protein extraction and immunoblotting (Fig.13a). Results demonstrated that in 
relation to shCntl-1 and -2 cells respectively, Spy1A inhibition was undetectable in 
shSpy1A-1 cells (2.5%) and shSpy1A-2 cells (-0.5%), and further corresponded to 
infection efficiencies ranging from 25-50% (Fig.13b-c). GFP-fluorescence was at its 
highest in lentiviral-transduced stable cell lines, and thus it was speculated that the 
maintenance of F5A1-2 cells beyond certain passages led to the acquisition of additional 
mutations and modifications in signal transduction pathways in response to long-term 
culturing. Alternatively, Spy1A knockdown may have been selected against as a result of 
continued cell passaging. Nevertheless, to determine whether modest Spy1A knockdown 
in stable F5A1-2 cell lines sufficed to affect tumor growth rate and ductal morphogenesis 
in vivo, F5A1-2
shCntl
 and F5A1-2 
shSpy1A
 cells were transplanted into the cleared fat pads of 
No. 4 inguinal mammary glands. Following transplantation, test subjects were sacrificed 
and freshly dissected 3, 6, 7, 10, or 15 days post-surgery. Representative photographs for 
each dissection time point are provided in Fig.25a, and showcase the anatomical changes 
associated with tumor development resulting from F5A1-2
shCntl
 and F5A1-2 
shSpy1A
 cell 
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injection. Up to 7 days post-surgery, shCntl-injected glands (left) generally exhibited an 
increase in tumorigenic potential in comparison to shSpy1A-injected glands (right) 
(Fig.25a). By day 10 post-surgery, however, tumors from either side had amalgamated 
into a single tumor mass and thus could not be distinguished effectively or subjected to 
calliper measurement of tumor height (Fig.25a). Consequently, overall tumor growth rate 
could not be determined accurately for test subjects co-transplanted with F5A1-2
shCntl
 and 
F5A1-2 
shSpy1A
 stable cell lines. Instead, as a more accurate measure, tumor nodule surface 
area was approximated per gland for the following time points: 3, 6-7, and 10 days post-
surgery (Fig.25b), and also was utilized to quantify changes in overall tumor size upon 
Spy1A knockdown. Up to 7 days post-surgery, F5A1-2
shSpy1A
 transplants gave rise to 
tumor nodules that exhibited a 2-fold reduction in overall tumor size, when compared to 
tumor nodules derived from F5A1-2
shCntl
 transplants (Fig.25b). Although the tumor 
growth pattern was less clear at 10 days post-surgery, shSpy1A-derived tumor nodules 
occupied less total surface area, as compared to shCntl-derived tumor nodules. Taken 
together, in vivo results obtained from Fig.25b demonstrate an overall reduction in tumor 
nodule size despite an apparent lack of Spy1A inhibition at the protein level. The trend 
was confirmed up to 10 days post-surgery, however, and replicates were too few to impart 
statistical significance to numerical data. Therefore, results are deemed preliminary at this 
stage, and will require further repetition in order to assess the validity of reduced tumor 
nodule surface area in response to shSpy1A treatment.       
     Tumor samples dissected from left and right glands on days 10 and 15 post-surgery 
were subjected to protein lysis and 10% SDS-PAGE analysis, coupled to immunoblotting 
for c-Myc, Spy1A, phosphorylated and total ERK1/2, p21, and Actin, the resident loading 
control (Fig.25c). Normalized to total Actin expression, all protein levels were quantified 
through densitometric analysis (Fig.25d). Confirmed through immunoblotting, persistent 
Spy1A knockdown was restricted solely to test subject No.231 (19%) and knockdown 
was virtually undetectable in No.235, whereas F5A1-2
shSpy1A
 tumors isolated from test 
subjects No.234 and 238 experienced a 10% and 3% elevation in Spy1A protein levels, 
respectively (Fig.25d). Thus, densitometry values indicated insignificant knockdown in 
three out of four shSpy1A tumor samples derived from late passage F5A1-2 cells (P63). 
Comparable to the expression patterns observed for Spy1A, c-Myc expression decreased 
91 
 
accordingly in test subjects No.231 (13%) and 235 (4%), however, increased in No.234 
(10%) and 238 (1%), relative to shCntl treatment (Fig.25d). The ratio of phospho-ERK1/2 
to total ERK1/2 was shown to decrease in F5A1-2
shSpy1A
 tumors derived from test subject 
No.231 (22%), however remained unaltered in tumors derived from No.234, 235, and 238 
(Fig.25d). In addition, three out of four test subjects (No.231, 234, and 238) experienced a 
slight reduction in p21 protein expression (<7%) (Fig.25d). Alternatively, p21 levels were 
upregulated by 19% in F5A1-2
shSpy1A
 tumors isolated from No.235, when compared to 
corresponding control tumors isolated from the same animal (Fig.25d). Despite negligible 
changes in Spy1A, c-Myc, ERK1/2, and p21 protein, densitometry values were utilized to 
predict general expression profiles in response to varying degrees of Spy1A knockdown 
(see Discussion). However, further replication must ensue in order to verify predictions.         
         
XIV. Stable Spy1A Knockdown Encourages In vivo Ductal Formation in Late Passage 
F5A1-2 Tumor Cells. 
     In vivo transplantation of stable F5A1-2 cell lines generates two distinct epithelial cell 
populations, namely (a) overgrown tumor masses and (b) epithelial ductal side branches, 
both of which are stained a dark purple colour by haematoxylin. Accordingly, it was 
speculated that whole mounts prepared 11 days post-surgery contained tumors too large 
in size to effectively observe all underlying networks of ductal side branches. Therefore, 
to investigate the effects of stable Spy1A knockdown on ductal morphogenesis at earlier 
stages of F5A1-2 tumor development, transplanted animals were sacrificed at 3, 6, and 7 
days post-surgery, after which fourth inguinal mammary glands were prepared for whole 
mount analysis through haematoxylin staining. Resultant whole mounts were examined 
under GFP fluorescence microscopy, and demonstrated an increase in the number of side 
branches produced upon transplantation of F5A1-2
shSpy1A
 cells, when compared to control 
treatments. Despite ineffective Spy1A knockdown, F5A1-2
shSpy1A
 whole mounts exhibited 
partial restoration of ductal side branching relative to control glands, although additional 
replicates are required to fully substantiate the statistical significance of whole mount 
data. Representative GFP-fluorescence images have been provided for left (shCntl-1) and 
right (shSpy1A-1) whole mounts derived from test subject No.229, whose fourth glands 
were isolated 6 days post-surgery (Fig.25e). 
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Figure 25. Stable Spy1A inhibition in late passage F5A1-2 cell lines induces MAPK 
Pathway and c-Myc downregulation and results in increased ductal morphogenesis in 
vivo. No. 4 inguinal mammary glands were cleared and transplanted with F5A1-2
shCntl
 cell 
suspension (left gland, L) at a dosage of 1x10
6
 cells per gland, and F5A1-2
shSpy1A
 cell 
suspension (right gland, R) at a dosage of 1x10
6
 cells per gland (N=13 replicates). Black 
arrows (→) point to the tumor nodule residing in each gland. Overall No. 4 mammary 
glands are outlined by a dashed black line (---). (a) A tumor time course was established 
upon dissection of six representative test organisms to determine the in vivo effect of 
stable shCntl and shSpy1A cell lines on the rate of tumor formation. The time points 
studied did not yield tumors that could be measured with a Vernier Calliper; instead, 
autopsy photographs are provided for each test subject, taken on the day of animal 
sacrifice and dissection to assess the rate of tumor growth in late passage stable F5A1-2 
cell lines: No.236 (day 3); No.237 (day 6); No.233 (day7); No.234 (day10); No.235 (day 
15); No.231 (day 15). (b) An estimated measure of surface area (cm
2
) was calculated for 
each tumor nodule per gland at a given time point (post-surgery). To enable comparative 
analysis between autopsy photographs, all surface area values were normalized to that of 
shCntl, and are reported as a final ratio. Black bars indicate shCntl tumor nodules (L 
gland); tan bars indicate shSpy1A tumor nodules (R gland). Accurate measurement of 
tumor nodule surface area was only feasible for select test organisms, based on autopsy 
photographs. Sample size per time point is provided above each set of bars. A minimum 
of two samples are required to calculated standard error; the standard error value at Day 7 
was determined to be + 0.01, but could not be calculated for remaining time points. (c) 
Whole tumor protein extracts were isolated from the periphery of L and R tumor tissues 
on days 10 and 15 post-surgery to avoid the mixed tumor population located in the centre 
of the organism. Protein analysis was conducted through 10% SDS-PAGE for L and R 
tumors isolated from No.231 (Control knockdown (C) 2, Spy1A knockdown (S) 2), 234 
(C3, S3), 235 (C1, S1), and 238 (C4, S4) animals (N=2 replicates, for each time point). 
Immunoblotting ensued for c-Myc (72 kD); Spy1A (31, 36 kD); phosphorylated ERK1/2 
(44 kD); total ERK1/2 (44 kD); p21 (21 kD); and Actin (43 kD), as a loading control. (d) 
Densitometric analysis was completed for the immunoblot depicted in (c); all protein data 
were subsequently normalized to total Actin expression. Spy1A (green); c-Myc (purple); 
p-ERK/total ERK ratio (blue); p21 (fuschia). (e) Whole mount L and R fourth glands 
were isolated from test subject No.229, 6 days post-surgery, followed by GFP-detection 
of epithelial ductal branches derived from GFP-tagged F5A1-2 stable cells. 
Representative images of ductal branching networks in shCntl (Panel 1-2) and shSpy1A 
(Panel 3-4) glands are shown over two different panels per gland, and depict various 
regions of each whole mount sample (4X magnification; N=1 replicate). 
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Discussion 
     De novo Spy1A overexpression typically equates with more aggressive, invasive BC 
phenotypes; in a separate report, deregulated c-Myc upregulation correlated strongly with 
advanced neoplastic mammary disease as well.
79-80
 Additionally, Spy1A and c-Myc 
mitogens localize to mammary epithelial cell types,
4,22
 and evidently function within the 
same temporal window during post-natal mammopoiesis: that is (a) both factors 
positively regulate proliferative developmental events (pregnancy), and (b) both are 
subject to upregulation during massive mammary gland remodelling and apoptosis 
(involution).
22
 Golipour and Myers et al. (2008) further identified Spy1A as an effective 
tumor promoter and downstream target of c-Myc, however only briefly alluded to the 
possibility that Spy1A functions as a positive mediator of de novo c-Myc signaling during 
mammary tumorigenesis.
22
 Therefore, results reported here are the first to classify Spy1A 
as an effector of c-Myc-induced tumor cell proliferation in vitro and in vivo, and further 
demonstrate that both proliferative regulators are co-elevated in c-Myc overexpressing 
mammary glands and associated tumor tissue.  
     I also demonstrate that E2 stimulation of ERa elevates Spy1A mRNA and protein 
expression through prerequisite MAPK pathway activity within the MCF7 cell system. 
Results derived from this report also suggest that c-Myc and Spy1A may function to 
downregulate the CKIs p21 and p27, respectfully, in those tumors overexpressing 
deregulated c-Myc, according to preliminary densitometry data utilized to extrapolate and 
predict changes in protein expression in response to MEK or Spy1A inhibition. 
Additionally, I provide preliminary evidence to suggest that MAPK signal transduction 
may function to regulate Spy1A protein expression in a positive and negative manner, 
depending on cellular context, and hypothesize that MAPK function is mediated by 
differential regulation of the MAPK machinery on a post-translational level. Ultimately, I 
postulate that the phosphorylation status of MAPK effectors determines the final outcome 
of MAPK signaling on Spy1A in c-Myc induced mammary neoplasias, and may facilitate 
the development of tamoxifen resistance in human BCs initially responsive to 
antiestrogen drug therapy.  
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I. Spy1A May Alter Cellular Distribution of p27 and Downregulate its Protein Expression 
in MMTV-Myc Overexpressing Tumors and Related F5A1-2 Cell Lines.   
     Furthermore, this study is the first to demonstrate that atypical upregulation of Spy1A 
persists in the novel F5A1-2 primary tumor cell line, and also correlates with increased de 
novo c-Myc protein expression and p27 downregulation. Although Spy1A is accredited 
for its ability to promote ubiquitin-mediated p27 proteolysis,
53,60,81
 I provide preliminary 
evidence to suggest that p27 is paradoxically upregulated together with Spy1A in tissue 
samples derived from MMTV-Myc overexpressing mammary glands and corresponding 
tumors. Similarly, immunohistochemical analysis of p27 expression in primary human 
mammary tumors revealed that 44% of studied tumors exhibited high p27 staining, 
whereas p27 was virtually absent in the rest.
82
 In support of its uncharacteristic role 
during cell cycle progression, p27 has been reported to assist in cyclin D-CDK4 complex 
formation, complex stabilization, and subsequent nuclear import to promote movement 
through G1/S.
83
 Also, Porter et al. (2003) revealed that Spy1A requires the presence of 
p27 substrate to properly stimulate cell transitioning through G1/S,
 
and it is further 
postulated that a certain threshold of p27 expression is indispensable for the continued 
maintenance of mammary tumor cellular proliferation.
32,53
 Perhaps during augmented 
G1/S in breast tumors, the tumor cell attempts to upregulate p27 in response to abnormal 
Spy1A elevation, and simultaneously strives to preserve the stoichiometric interaction 
between p27:Spy1A. Consequently, a surplus of functional p27 may be available to bind 
to additional molecules of nuclear localized Spy1A. Thus, enhanced association of Spy1A 
with its CDK2 binding partner after direct interaction with p27 may potentiate the rate of 
p27 phosphorylation at residue Thr-187,
60
 and could possibly prime p27 for additional 
phosphorylation events that function to initiate cytoplasmic relocalization of p27 prior to 
its degradation. Rodier et al. (2001) demonstrated that in vivo phosphorylation of p27 on 
Ser10 results in its stabilization in a manner that does not impede SCF
Skp2
-mediated 
proteolysis of p27.
84
 Given that p27 exits the nucleus upon mitogen-activated Ser10 
phosphorylation,
84-85
 the possibility arises that p27 in its  phosphorylated form is subject 
to transient stabilization in the cytoplasmic fraction of tumor cells, which may account for 
the increased detection of p27 levels in MMTV-Myc overexpressing mammary tumors. 
Numerous studies have also highlighted the importance of differential phosphorylation as 
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a modulator of p27 function,
84,86-89
 and based on the visualization of two protein bands 
resulting from p27-directed immunoblotting (Fig.9), I predict that p27 exhibits multiple 
phosphorylation states during mammary tumorigenesis. Moreover, the argument that two 
protein bands signify the existence of more than one p27 isoform in MMTV-Myc glands 
and tumor tissue is highly refutable, since no evidence is currently available to support in 
vivo synthesis of alternate p27 splice variants. 
     Short-term retention of cytoplasmic p27 can precede its subsequent degradation during 
G1/S, consistent with the notion that p27 regulates processes such as cell migration and 
possibly apoptosis, when relocated to the cytoplasm.
85,90-91
 For instance, consistent with 
its cell cycle role, p27 can functionally inhibit Grb2, an upstream mediator of Ras/MAPK 
signaling, when persistently confined to the cytoplasm.
85,92-93
 Conversely, yeast-two 
hybrid screening conducted by Sugiyama et al. (2001) identified the novel ability of Grb2 
and Grb3-3 adaptor molecules to interact with p27 in the cytoplasm both in vitro and in 
vivo, and further demonstrated the essentiality of the Grb2-p27 interaction for successful 
proteolytic destruction of cytoplasmic p27, utilizing NIH3T3 fibroblasts.
94
 In this way, 
the MAPK cascade is postulated to be integral for the negative regulation of p27 in c-Myc 
deregulated BCs. In support of this hypothesis, MEK1 inhibition in proliferating HC11 
cells promoted a slight increase in p27 expression, although changes in protein expression 
were essentially negligible and additional replicates are required to confirm the validity of 
this result. Possibly confounded by the absence of functional p53, whether this outcome 
was an immediate by-product of Spy1A downregulation remains to be elucidated. At 
present, it has not been established whether MAPK signaling mediates Spy1A through a 
direct or indirect mechanism. Based on previous reports,
95
 I postulate that MAPK signal 
transduction may play a role in regulating Spy1A expression by relieving the inhibitory 
action of p27 on CDK2, thereby permitting Spy1A/CDK2 association and consequential 
cell cycle movement. In support of this hypothesis, Donovan et al. (2001) demonstrated 
the essentiality of MAPK signaling for maintaining tamoxifen resistance in numerous BC 
cell lines through posttranslational mechanisms that serve to modify p27 phosphorylation, 
downregulate p27 protein levels, and strive to relieve p27 inhibition of CDK2 activity.
95
 I 
also predict that c-Myc-stimulated Spy1A protein indirectly promotes the shuttling of 
phosphorylated p27 to the cytoplasm in mammary tumor cells that overexpress c-Myc. 
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More specifically, I hypothesize that upon complex formation in the nucleus, Spy1A-
tethered p27 may relocate to the cytoplasm where it experiences brief stability due to its 
interaction with Spy1A, which ultimately permits p27 to rapidly associate with other 
cytosolic factors prior to inevitable CKI destruction during G1/S.  
 
II. Late Passage F5A1-2 Tumor Cells May Acquire Additional Mutations and/or Genetic 
Lesions During Long-Term Cell Culture. 
     Immunoblotting data accumulated from this study represent only a limited snap-shot 
of the dynamic signaling events required to maintain p27 downregulation and tumor 
promotion due to a reliance on the  time of protein isolation, which is thought to explain 
inconsistencies in p27 expression observed across different tumor samples and cell lines. 
Immunoblotting was utilized to examine whole tumor changes in cell signaling and did 
not account for the presence of heterogeneous cell populations that typically inhabit 
mammary tumors. Alternatively, prolonged episodes of cell passaging often select for a 
single cell population, and cell culturing over extended periods is thought to promote the 
accumulation of genetic abnormalities or added mutations in F5A1-2 cells, accounting for 
discrepancies in tumor signaling that may have occurred over time. Indeed, Tainsky et al. 
(1984) attributed the altered tumorigenic capacity of late passage PA1 teratocarcinoma 
cells to spontaneous development of a guanine-to-adenine point mutation within the 
human ras
N
 oncogene, following transplantation into nude mice.
96
 In addition, PA1 
teratocarcinoma cells were initially isolated from a primary tumor source, analogous to 
the derivation of F5A1-2 cell lines.
96
 Instead, live imaging of de novo murine mammary 
tumors may evade the above issues by successfully capturing all phases of fluorescently-
labelled Spy1A, c-Myc, and p27 localization during tumor progression, thereby revealing 
the full scope of protein activity rather than focusing on one instance of time. This 
approach may especially benefit future analysis of c-Myc at the mRNA level, due to its 
hasty transcriptional activation and its nature as an immediate early gene.    
 
III. Tamoxifen Resistance Is Thought to Arise from Constitutive c-Myc Overexpression 
and p21 Downregulation in Response to Persistent E2 Stimulation. 
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     In response to estradiol exposure, ERa typically functions to promote rapid movement  
through G1/S by use of a mechanism that is contingent upon transcriptional activation of 
c-Myc and concomitant downregulation of p27.
28
 Additionally, MCF7 cells pre-treated 
with estrogen-deactivating agents like tamoxifen respond to both c-Myc upregulation and 
E2 stimulation by downregulating p21 mRNA and protein expression, thus demonstrating 
the importance of c-Myc as a critical mediator of ERa activity.
28
 Utilizing a tamoxifen 
resistant version of MCF7 cells, designated as LCC9 hereafter, Mukherjee and Conrad 
(2005) further revealed that c-Myc and p21 are no longer altered by estrogen or tamoxifen 
application during antiestrogen resistance; instead c-Myc is employed as a transcriptional 
repressor of p21,
28
 although its effect on Spy1A in a tamoxifen resistant paradigm has 
never been examined. Therefore, I recommend that LCC9 cell lines be utilized in future 
studies to clarify the role played by Spy1A in BCs that strangely circumvent antiestrogen-
mediated tumor regression. Furthermore, LCC9 cell stocks have recently been obtained 
from the Lombardi Cancer Centre (Washington, DC, USA) for immediate analysis. Of 
notable interest, past reports have put forth the idea that c-Myc actively facilitates the 
acquisition of an antiestrogen resistance phenotype in ERa-positive breast tumors, and 
does so by downregulating p21 protein levels.
28
 Although results are strictly preliminary, 
I provide evidence to support this conjecture by verifying p21 reduction by 20% in the 
presence of E2 in wild-type MCF7 cell lines (Fig.16), as previously reported.
28,97-98
 Also, 
c-Myc upregulation generally correlated with p21 downregulation and vice versa, and this 
pattern continually emerged in differentially treated mammary cell lines throughout the 
course of this study (HC11, MCF7, F5A1-2). Hence, in response to first-line antiestrogen 
drug treatment, the following mechanism may have evolved within ERa-positive BCs to 
counteract the inhibitory action of tamoxifen on ERa, thereby promoting persistent cell 
proliferation and tamoxifen insensitivity. In the presence of sustained E2 stimulation, c-
Myc is thought to become rapidly upregulated by ERa and subsequently suppresses p21 
promoter activity, while simultaneously activating Spy1A, which ultimately functions to 
promote p27 inactivation. Furthermore, once Spy1A has been transcriptionally stimulated 
by E2, it may continue to activate c-Myc through a positive feed-back loop. However, 
further investigation is needed to clarify the feasibility of this mechanism in mediating the  
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development of antiestrogen resistance.       
 
IV. ERa Induction of Spy1A mRNA and Protein Expression May Be Mediated 
Preferentially Through the MAPK Cascade.  
     Generally speaking, E2 treatment induces Spy1A protein expression as early as 2 h 
post-administration in wild-type MCF7 cells, and progressively elevates Spy1A mRNA 
expression throughout the entire 24 h time course, thereby marking this study as the first 
to link ERa activation to Spy1A upregulation. In an accelerated fashion, E2 has been 
shown previously to stimulate ERK1/2 expression as early as 5 minutes post-treatment in 
various cell lines including the MCF7 cell model, and E2-directed ERK1/2 upregulation 
is postulated to occur via activation of plasma membrane-bound ER.
73
 Additionally, 
Golipour and Myers et al. (2008) identified Spy1A as a downstream target of the MAPK 
pathway.
22
 In this study, evidence obtained from the chemical inactivation of MEK1/2 in 
estrogen-responsive MCF7 cells revealed the necessity of MAPK signaling for mediating 
E2 stimulation of Spy1A protein expression as early as 2 h post-U0126 treatment, and 
further identified MEK1/2 isoforms as novel upstream mediators of Spy1A, as previously 
predicted.
22
 However, ambiguity exists as to whether the MAPK pathway exerts positive 
or negative regulation over Spy1A, particularly since Spy1A protein levels experience 
persistent elevation following MAPK inhibition in late passage F5A1-2 cells. Although 
results are preliminary, they suggest that MAPK signaling may play an integral role in 
regulating Spy1A, whether through direct MAPK activation or through indirect regulation 
of downstream target genes. However, the mechanism through which this process occurs 
is currently unidentified, but is thought to rely on cellular context and tumor genotype.  
 
V. MAPK and c-Myc Cross-talk May Not Affect Spy1A Protein Expression During c-Myc 
Induced Mammary Tumorigenesis. 
    During tumorigenesis, mutations localized to the ras
 
oncogene bring about relentless 
activation of the MAPK pathway in ~30% of human malignancies and in ~5% of BCs.
96
 
In addition, upregulation of ERK1/2 has been reported in numerous tumor cell lines.
96
 
Moreover, MAPK signaling typically induces the transcription of immediate early genes 
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like c-fos, c-jun, and c-myc in response to hormonal, mitogenic, phorbol ester, or growth 
factor stimuli.
96
 Contrary to these reports, however, MEK1/2 inhibition failed to alter c-
Myc protein expression in MCF7 cells (Fig.16), as previously documented by Lobenhofer 
et al. (2000),
73
 thereby suggesting that c-Myc and MAPK cross-talk may be dispensable 
for MAPK-mediated Spy1A regulation at the protein level. Hence, I predict that MAPK 
signaling mediates Spy1A function independently of c-Myc protein status. On a similar 
note, the ability of E2 to stimulate Spy1A (mRNA, protein) through c-Myc activation is 
currently unknown, and warrants further investigation. Consequently, c-Myc knockdown 
via transient transfection of MCF7 cell cultures with dominant negative Myc constructs or 
c-Myc short interfering RNA may be conducted to clarify whether ERa requires c-Myc to 
upregulate Spy1A. Lastly, it remains unclear whether MAPK-mediated Spy1A regulation 
relies on the constant synthesis of c-Myc mRNA transcripts. Resolving mRNA expression 
profiles of ERK1/2, Spy1A, and c-Myc under identical experimental conditions may be 
utilized to elucidate this aim in future studies.  
 
 VI. Spy1A May Mediate the Development of Tamoxifen Resistance in Human BCs That 
Initially Respond to Antiestrogens. 
    During the initial phases of antiestrogen drug treatment, it is speculated that tamoxifen 
induces conformational changes in ERa structure in order to inhibit estrogenic signaling, 
i.e. ERa targets that promote tumor cell proliferation and other pro-estrogenic effects.
12
 
Although tamoxifen effectively targets ERa when utilized to treat antiestrogen responsive 
breast tumors, development of tamoxifen resistance often hinders the effective treatment 
of unresponsive BCs.
12
 Instead, antiestrogen resistant breast tumors may benefit greatly 
from treatment strategies that involve targeting downstream effectors of ERa in order to 
reduce tumor cell proliferation. Preliminary data imply that Spy1A may function as a 
putative downstream target of ERa (Fig.15), and upon transient inhibition, Spy1A is also 
able to significantly reduce cell population density in vitro (Fig.11). Derived from ERa-
positive, ERb-negative MCF7 cells,
12
 preliminary results further demonstrate the inherent 
ability of E2 to upregulate Spy1A mRNA and protein via preferential activation of ERa. 
In addition, the DNA binding activity and expression levels of ERa remain intact during 
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tamoxifen resistance, thereby promoting protein interaction between ERa and the c-jun 
component of the AP-1 transcription factor complex
101
 and maintaining ERa signaling in 
the presence of antiestrogens. In this way, ERa:AP-1 cross-talk may indirectly contribute 
to the deregulation of Spy1A expression in a manner independent of E2 stimulation.     
     Also, tamoxifen is able to stimulate ERa coactivators that function to maintain ERa 
signaling despite antiestrogen presence.
99
 As a result, tumor cells may develop tamoxifen 
resistance.
99
 For instance, tamoxifen may activate AP-1 regulated genes in the presence of 
E2 by upregulating AP-1 transcriptional activity, in one mechanism.
99-100
 In turn, elevated 
AP-1 levels may trigger a negative feedback loop that caters to tamoxifen resistance, as 
evidenced by the acquisition of a drug-resistant phenotype in MCF7 cells overexpressing 
c-jun.
99-100
 Furthermore, when compared to untreated ER-positive pair matched samples, 
tamoxifen resistant human BCs often display enhanced activity of c-Jun NH2-terminal 
kinase, a potent inducer of AP-1, and exhibit increased binding of AP-1 to its respective 
promoter elements.
99,101
 Close examination of the putative Spy1A promoter reveals two 
AP-1 response elements positioned at nucleotides -715 and -630 in reference to the 
transcription initiation start site (position 0). However, whether Spy1A falls under AP-1 
regulation during antiestrogen resistance warrants further examination. Hence, I postulate 
that in response to prolonged exposure, tamoxifen indirectly upregulates Spy1A protein, 
by promoting AP-1 binding to the Spy1A promoter in ERa-positive BC cells. In this way, 
enhanced AP-1 binding to the Spy1A promoter may exert transcriptional regulation over 
Spy1A. Furthermore, c-Jun overexpression
100
 and Spy1A downregulation (Fig.14) appear 
to promote comparable changes in BC cell phenotype, suggesting that AP-1 responds to 
tamoxifen treatment by transcriptionally repressing Spy1A signaling, and in this way may 
disrupt the ability of Spy1A to regulate MAPK through a positive feed-back loop.   
     Data derived from normal mammary HC11 cells suggest a putative link omnipresent 
between MAPK and c-Myc signaling under controlled proliferative circumstances in the 
mammary organ (Fig.17), although MAPK inhibition was pronouncedly weak relative to 
results generated by Golipour and Myers et al. (2008).
22
 However, the strength of this link 
appears to greatly diminish during mammary tumorigenesis as evidenced by unfaltering 
levels of c-Myc in U0126-treated MCF7 cells partially deficient in ERK1/2 expression 
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(Fig.16b). Furthermore, the degree to which MAPK signaling regulates Spy1A expression 
during normal mammary development has not been determined, although based on data 
from Fig.17b, an important role may exist for functional MAPK signaling in promoting 
Spy1A-mediated epithelial mitogenesis in healthy mammary cells. Moreover, the protein 
stability of c-Myc is regulated via phosphorylation on multiple residues,
40
 and ERKs that 
undergo constitutive phosphorylation dually phosphorylate c-Myc on Thr-58 and Ser-62 
residues, and are thought to promote c-Myc self suppression.
40
 Cyclin/CDK complexes 
phosphorylate c-Myc on Ser-62 as well.
40 
Considered together, these findings imply that 
in the absence of functional MAPK signaling, c-Myc may no longer be suppressed and 
becomes subject to upregulation. Therefore, should AP-1 antagonize Spy1A expression, I 
predict that Spy1A may no longer exert positive regulation over MAPK signaling, leading 
to inactivation of the MAPK cascade. This phenomenon may encourage c-Myc to escape 
MAPK-mediated inhibition, thereby promoting upregulation of c-Myc and inadvertent re-
activation of Spy1A expression. The resultant positive feed-back loop speculated to exist 
between Spy1A and c-Myc, based on results from Fig.11, may continue to promote tumor 
propagation in the presence of tamoxifen treatment, possibly leading to the acquisition of 
antiestrogen resistance.  
 
VII. Transient Spy1A Downregulation May Participate in Early Stages of EMT in Murine 
and Human BCs Overexpressing Deregulated c-Myc. 
     In addition to promoting tamoxifen resistance in vitro, MCF7 cells that exogenously 
overexpress c-Jun closely mimic the cellular properties of the epithelial to mesenchymal 
transition (EMT) such as enhanced cell motility, upregulation of AP-1 regulated type IV 
collagenase protein (MMP-9), and marked elevation in invasive capacity.
100
 EMT is 
traditionally defined as a developmental process utilized by embryonic cells of epithelial 
origin to gain motile properties and escape their local cellular niche to ectopic sites, in 
order to expand into mesoderm and other differentiated tissue.
102
 Epithelial cells residing 
in breast tumors have also been postulated to differentiate into stromal tissue.
26
 Numerous 
experimental models have verified a central role for EMT during mammary tumor 
progression into more invasive, metastatic forms of BC, highlighted in primary tumor 
cells by a loss of epithelial cell fate and morphological transformation into a fibroblastic, 
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spindle-like cell state.
102-105,112
 In the F5A1-2 cell system, EMT-like changes were 
reported 24 h after Spy1A shRNA treatment. In response to ~40% knockdown of Spy1A, 
early passage F5A1-2 cells (<P30) appeared to undergo morphological changes in cellular 
phenotype, thereby yielding a higher population of spindle shaped, myoepitheliod-like 
cell types in relation to wild-type and control shRNA treated cells, prompting further 
investigation. It was speculated that a forced reduction in cell proliferation rate as a result 
of transient Spy1A silencing (Fig.14a) may have physically expanded the availability of 
unoccupied plate surface area, potentially allowing remaining live cells to monopolize the 
additional space by protruding outwards to neighbouring cells rather than falling victim to 
morphological transformation. Alternatively, variances in cellular phenotype may have 
resulted from changes in signal transduction and pathway networking/cross-talk, 
particularly since Spy1A inhibition has been shown to downregulate ERK1/2 and c-Myc 
protein expression. To clarify whether Spy1A inhibition influences mammary tumor cell 
morphology, luminal epithelial markers CK18 and CK19 were analyzed in response to 
RNAi treatment in both early (<P30) and late (>P60) passage F5A1-2 cells, since Spy1A 
expression was thought to vary with passage number. Consistent with this paradigm, 
transitory inhibition of Spy1A in earlier passages consistently produced changes in tumor 
morphology indicative of EMT, implying cell reversion to a fibroblastoid state and 
further supported by a 31% reduction in CK18 expression. Note that CK18 is a structural 
marker typically utilized in mammary gland tumor literature to detect cells of epithelial 
lineage.
70
 Immunoblotting for CK19, yet another luminal epithelial marker,
106
 resulted in 
no detection of CK19 protein in both control treated and Spy1A-abrogated F5A1-2 cells 
(data not shown). As a result, it could not be verified whether Spy1A attenuation 
promoted the acquirement of a fibroblastic or myoepithelial cellular phenotype indicative 
of EMT. At the very least, Spy1A downregulation may act as a potential initiator of EMT 
during its earliest stages, however the expression profile of Spy1A during all phases of 
EMT has not yet been identified. Additional insight into the molecular changes associated 
with epithelial to mesenchymal transitioning may be obtained from flow cytometry- 
mediated assessment of myoepithelial markers (smooth muscle actin, vimentin)
106
 in 
F5A1-2 cell populations treated with Spy1A RNAi. 
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VIII. F5A1-2 Cell Lines and Associated Tumor Tissue May Alter Tumorigenic Signaling 
and Tumor Phenotype in Response to Spy1A Knockdown. 
     As stated in the Results section, preliminary findings from Fig.24b and Fig.25d have 
been utilized to predict the degree to which c-Myc and MAPK expression profiles vary 
when challenged with Spy1A knockdown. In combining in vivo expression data from test 
subjects No.106, 107, and 231, Spy1A protein levels were significantly reduced in tumor 
samples derived from shSpy1A-treated F5A1-2 cells, when compared to shCntl treatment 
(p=0.035, Student’s t-test, 1-tail distribution, unequal variance). Likewise, ERK1/2 and c-
Myc protein levels were significantly downregulated in shSpy1A tumor samples, relative 
to shCntl treatment (p<0.05, Student’s t-test, 1-tail distribution, unequal variance). Thus, 
disregarding variables such as passage number of transplanted cells or post-surgery time 
elapsed upon tumor extraction, it is speculated that significant levels of Spy1A inhibition 
downregulate c-Myc and MAPK protein expression in c-Myc overexpressing BCs.  
     Although transient transfection assays are typically utilized to assess short-term effects 
of transgene expression, F5A1-2 cells transfected with shSpy1A constructs continued to 
exhibit Spy1A knockdown (Fig.24b) and reduced tumor growth rate (Fig.22d) up to 30 
days post-surgery in select tumor samples, relative to shCntl treatment. Hence, transient 
Spy1A inhibition is thought to have slowed the process of cell transformation by reducing 
cell population size, and/or preventing cells from undergoing morphological changes that 
promote tumor cell proliferation.  
     For the purpose of examining long-term consequences of Spy1A abrogation, lentiviral 
transduction assays were utilized to generate stable F5A1-2 cell clones that constitutively 
overexpressed shCntl or shSpy1A constructs. Spy1A knockdown was initially successful 
in late passage (P63) stable cell lines, as evidence by a 30% reduction in Spy1A protein 
expression (Fig.12), however protein lysates extracted two passages later (P65) exhibited 
insignificant knockdown (Fig.13). It was speculated that prolonged cellular passaging led 
to the acquisition of a knockdown resistant phenotype due to F5A1-2 development into an 
advanced, aggressive form of BC. Similarly, P60 cell lines were resilient to 10 mM U0126 
and PD098059 inhibition, suggesting that MAPK inhibitors are ineffectual in treating late 
stage mammary neoplasias overexpressing c-Myc. Although infection efficiencies ranged 
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from 25-50%, Spy1A protein levels were not effectively silenced in tumor lysates derived 
from F5A1-2
shSpy1A
 stable cells cultured to P65, lending credence to the idea that these 
cells produce late stage tumors that no longer respond to conventional treatment methods. 
Furthermore, whole mounts transplanted with F5A1-2
shSpy1A
 cells displayed an increase in 
ductal side branching relative to control glands, despite insignificant Spy1A knockdown. 
These data suggest that partial silencing of Spy1A in only a portion of the tumor 
population may still be sufficient to reduce tumor growth rate, ductal epithelial side 
branching, and c-Myc and MAPK signal transduction, although additional replicates are 
needed to impart statistical significance. Furthermore, this phenomenon also suggests that 
in vivo Spy1A knockdown may restore BCs undergoing later stages of tumor progression 
to less aggressive neoplastic states, possibly by disrupting the necessary changes in cell 
phenotype responsible for cell transformation. Therefore, potential exists for Spy1A to be 
targeted clinically in order to reduce the severity of BCs overexpressing c-Myc. 
 
IX. Transient and Stable Spy1A Knockdown Reduces Cell Proliferation Rate in F5A1-2 
Cells and Partially Restores Ductal Epithelial Branching In vivo. 
     When targeted with Spy1A RNAi, F5A1-2 cell lines experience a significant reduction 
in tumor cell proliferation rate, as supported by in vitro and in vivo evidence. Transient 
Spy1A knockdown in mid-passage (P31) F5A1-2 cell lines resulted in a ~12% decrease 
in cell number in response to a single transfection round. Even more prominently, F5A1-2 
cells that were subjected to two rounds of transfection experienced a ~50% decrease in 
overall cell number, thereby implicating Spy1A as a robust tumor promoter, in addition to 
highlighting its nature as a downstream effector of c-Myc. Moreover, as evidenced by 
persistent downregulation of c-Myc in response to Spy1A RNAi in early to mid-passage 
F5A1-2 cell lines, I predict that the mechanism by which c-Myc promotes tumor cell 
proliferation relies on constitutive activation of Spy1A expression, based on preliminary 
findings. In support of this notion, immunoblotting data obtained from in vivo tumor 
analysis closely mirrored in vitro results, and demonstrated that Spy1A inhibition reduces 
tumor growth rate, as evidenced by an 11% decline in overall tumor height. Consistent 
with these data, a decrease in tumor cell proliferation was evident in autopsy photographs 
taken during early post-surgery time points (Fig.25a). However, the relationship between 
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Spy1A inhibition and reduced growth rate generally diminished during later time points, 
and was thought to result from insufficient knockdown in late passage F5A1-2 tumor 
cells. Further analysis, however, will clarify the role of Spy1A during c-Myc deregulated 
BC across different cell passages.  
     Additionally, Golipour and Myers et al. (2008) previously reported that constitutive 
Spy1A activation in a non-tumorigenic HC11 setting leads to premature epithelial ductal 
development through enhanced TEB sprouting and elevated ductal side branching, in 
vivo.
22
 I extrapolate these data by further showing that transplantation of untreated F5A1-
2 cells into cleared mammary fat pads appears to decrease the ductal side branch number. 
Furthermore, the emergence of rudimentary TEB structures in F5A1-2 glands appeared to 
be less differentiated than the mature ducts observed in the contralateral saline-injected 
gland (Fig.23a), suggesting that F5A1-2 transplantation may reduce the rate of ductal 
formation in vivo. However, findings are preliminary and should be replicated to confirm 
whole mount observations. Most intriguing was the ability of Spy1A silencing to increase 
epithelial ductal morphogenesis in vivo, as evidenced by an increase in ductal side branch 
number when compared to shCntl treated glands (Fig.23b-c, Fig.25e). Hence, based on 
whole mount observations, I hypothesize that although homeostatic levels of Spy1A may 
promote normal ductal formation during typical mammary development, the rate of tumor 
proliferation may be too advanced in F5A1-2 tumors to allow for proper establishment of 
the mammary ductal tree, as a result of Spy1A and c-Myc co-elevation. Ultimately, it is 
suggested that inhibition of Spy1A activity in human BCs overexpressing c-Myc may be 
therapeutically relevant, in that complete Spy1A disruption may lead to irreversible tumor 
regression and may even increase favourable prognosis when utilized in combination with 
or supplementary to antiestrogen chemo-preventative agents.   
     To fully understand the intracellular mechanism governing Spy1A inhibition, I report 
here the novel design of five shRNA constructs targeted against various regions of the 
Spy1A transcript. Corresponding protein regions are portrayed in Fig.6, and reveal that 
constructs three and four fall within the conserved Speedy/RINGO box (amino acids 66-
206),
18-19
 whereas remaining constructs are positioned external to this region. Whether 
constructs that correspond to the Speedy/RINGO box yield the uppermost levels of 
Spy1A knockdown is unknown. Thus, this hypothesis may be tested through transient 
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transfection of F5A1-2 cell lines with each of the four remaining constructs, followed by 
quantification of GFP-fluorescence as an approximate measure of shRNA expression. 
Also, since Spy1A knockdown was derived solely through construct two, prospective 
experiments will benefit from utilizing all five constructs to highlight the full spectrum of 
effects that result upon its inhibition, since it has been established that each shRNA 
construct possesses a differential capacity to effectively attenuate target gene expression 
for reasons that are not completely understood.
107
 Additionally, the utilization of multiple 
RNAi constructs to validate all outcomes of Spy1A inhibition is typically required to 
confirm that knockdown effects are not attributed to the vector alone. However, use of a 
scrambled shRNA construct that does not bind to or recognize the Spy1A transcript 
serves as an excellent starting point to verify the ability of each Spy1A construct to 
functionally repress target gene expression. In this way, if RNAi repression results in total 
cell lethality, other constructs exist to assess the partial inactivation of Spy1A, in order to 
determine its entire spectrum of effects on mammary development and tumorigenesis. In 
relation to post-natal mammopoiesis, I postulate that downregulating Spy1A in luminal 
epithelial mammary tumor cells to basal levels observed in mammary development may 
restore the underlying TEB developmental program that has been initially subjected to 
deregulation by induction of c-Myc overexpression under the MMTV-promoter.  
 
X. Caveats Associated with Mammary Fat Pad Transplantation, Whole Mount Analysis, 
and Utilization of pLB to Knockdown Spy1A In vivo. 
     Although pLB has been documented previously to effectively silence target gene 
expression in diabetic mouse models under mouse U6 promoter control, pLB does not 
harbour a mammalian selection marker. Instead, pLB has been engineered to express GFP 
under control of the mammalian CMV promoter, to produce green fluorescence upon 
successful shRNA expression.
108
 One method to circumvent the issues observed when co-
transplanting shCntl and shSpy1A treated F5A1-2 cells within the same organism, is to 
replace the GFP gene – located within the control shRNA pLB vector – with another 
fluorescent gene such as YFP. In this way, it can be determined whether Spy1A shRNA 
treated F5A1-2 cells do in fact produce more invasion into the contralateral gland upon 
transplantation into cleared fat pads. Also, the implementation of different fluorescence 
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markers may be utilized to confirm that Spy1A knockdown is in actuality reducing tumor 
growth rate in vivo. Although late passage stable F5A1-2 cell lines provide us with some 
insight into the signaling changes invoked by Spy1A attenuation, lentiviral infection of 
early passage F5A1-2 cell lines (P3) with control or Spy1A shRNA constructs should be 
conducted. Subsequent transplantation into cleared mammary glands should also be 
repeated with these new stable cell lines to determine the outcome(s) of Spy1A inhibition 
during the earliest stages of c-Myc induced tumorigenesis. Furthermore, development of a 
Spy1A knockout mouse model will provide several advantages over utilizing lentiviral 
transduction in order to study the effects of complete Spy1A abrogation on pre-natal and 
post-natal mammary development, morphogenesis, and lactation. On a concluding note, 
carmine alum staining produces clearer visualization of epithelial ductal side branches in 
comparison to haematoxylin staining, as evidenced by virtually no background staining in 
carmine treated whole mounts depicted by Golipour and Myers et al. (2008).
22
 In stark 
contrast, whole mount glands stained with haematoxylin (Fig.23) exhibited high levels of 
pink background, thereby impeding proper analysis of epithelial ductal branching. Hence, 
it is recommended that future studies utilize carmine alum staining to assess phenotypic 
changes in mammary ductal morphogenesis. 
 
XI. Assessing the Role of Spy1A in Initiating Mammary Tumor Formation is Now 
Feasible Due to Creation of the First MMTV-Spy1A Transgenic Murine Model.  
     Golipour and Myers et al. (2008) previously reported that Spy1A displays intrinsic 
tumor promoting activity and is able to enhance mammary tumor formation upon stable 
adenoviral-induced overexpression in transplanted syngeneic HC11 cell lines.
22
 However, 
whether Spy1A can actively induce tumorigenesis has not been ascertained.
22
 Therefore, 
to elucidate the role of Spy1A in tumor initiation and mammary gland development, I 
derived the first transgenic FVB mouse model engineered to overexpress Spy1A under 
control of the MMTV promoter. Chosen for its success in previous publications, the 
MMTV promoter has been demonstrated to specifically target transgene expression to the 
mammary epithelium of glands, rather than to surrounding stromal layers.
46,48,109
 The 
MMTV-SV40-Spy1A transgene comprises the following components in the following 
order: (a) MMTV-LTR promoter/enhancer, (b) c-Ha-ras 5’ UTR, (c) Spy1A cDNA 
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sequence excised from the Spy1A-flag-pLXSN vector, as previously described in the 
Materials and Methods section of this thesis, and (d) SV40 small-t intron and poly(A) tail 
sequences. It is important to note that the SV40 small-t intron was previously integrated 
into the vector backbone due to its enhancement of transgene expression in vivo.
110
 Five 
rounds of pronuclear injection of the MMTV-SV40-Spy1A transgene have already been 
conducted, resulting in production of two litters, thus far. Tail clips will be excised on 
December 14
th
 and 21
st
 of the calendar year, and will further require genotypic analysis to 
identify MMTV-Spy1A transgenic organisms.
111
 In this way, the effects of constitutively 
active Spy1A expression on early placode formation and mammary ductal morphogenesis 
may be elucidated.     
 
XII. Concluding Remarks and Future Directions.  
     Despite recognizing the importance of Spy1A signaling for c-Myc induced mammary 
tumorigenesis, numerous questions remain unanswered. Confirmation of Spy1A mRNA 
silencing in F5A1-2 cell lines may determine whether Spy1A mediates c-Myc expression 
on a transcriptional level, and will reveal the degree to which Spy1A is transcriptionally 
silenced. Thus, it is recommended that future mRNA studies be conducted by utilizing a 
quantitative real time PCR approach. Moreover, since it has been suggested that Spy1A, 
c-Myc, MAPK, p27, and p21 protein levels fluctuate between different cell passages, it 
will be important to determine the signaling signatures for each of these factors across P3, 
P31, and P60 passages of F5A1-2 cell lines. Likewise, assessing the status of ERa across 
cell passage will assist in determining whether F5A1-2 cells initially probe positive for 
ERa, but may lose expression as a result of tamoxifen resistance. Hence, F5A1-2 may 
represent a novel tamoxifen resistant cell model that constitutively overexpresses c-Myc. 
Consequently, if cells are shown to be unresponsive to tamoxifen treatment, this outcome 
may further imply acquisition of an antiestrogen resistance phenotype due to deregulated 
c-Myc expression. Instead, if F5A1-2 cells are characterized as ERa-negative and do not 
respond to tamoxifen, they may exhibit de novo/intrinsic drug resistance.  
     Protein localization may also be utilized to establish the tissue and cellular distribution 
of ERa, Spy1A, c-Myc, MAPK, p27, and p21, and may clarify their function during c-
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Myc induced tumorigenesis when examined in F5A1-2 cell lines differentially treated in 
the following manner: (a) control or Spy1A RNAi, (b) c-Myc knockdown via transfection 
of dominant negative Myc constructs or c-Myc short interfering RNA, and (c) MAPK 
inactivation utilizing U0126 and PD098059 inhibitors. Additionally, localization studies 
may be expanded to other cell culture models (HC11, MCF7, LCC9). Furthermore, the 
putative promoter of Spy1A has been predicted to contain ERa (-900) and c-Myc (-880) 
response elements adjacent to one another, suggesting that both transcription factors may 
function to transcriptionally regulate Spy1A. Therefore, chromatin immunoprecipitation 
analysis may be utilized to determine the importance of ERa and c-Myc for stimulating 
Spy1A at the mRNA level. On a final note, resolving the role of Spy1A during tamoxifen 
resistance, through comparative analysis of wild-type MCF7 and LCC9 cell lines may 
determine whether Spy1A can be identified as a clinically relevant target for aggressive 
human BC forms, with particular focus on relapsing ERa-positive mammary neoplasias 
classified under antiestrogen resistance.  
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Vector Map for MMTV-SV40-Spy1A 
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Anaesthetizing a Mouse 
(Protocol obtained and adapted from L.A. Porter) 
 
 
Note: 
A mouse should not be under for more than 20 minutes; after this time, it becomes 
more difficult to bring them back. 
 
      -  fill up isoflurane machinery 
      -  open oxygen tank 
      -  turn on isoflurane machinery 
                - move nozzle until the red bulb sits at level "3" 
      -  check hoses and make sure they connect from the oxygen input to the isoflurane 
      -  place mouse in anaesthetizing chamber  
                - make sure gas hose is connected to the chamber 
      -  turn on isoflurane to level 0.5 for 30 seconds. 
                - slowly increase in increments of 0.5 until you reach 2.5 
      -  when mouse is fully under, perform the following steps: 
                - remove mouse from chamber and put on the mouthpiece 
                - switch the isoflurane hose from the chamber to the mouthpiece, also 
      -  give mouse eye drops to prevent drying out during surgery 
      -  when surgery is complete: 
                - remove mouse from mouthpiece and return to chamber 
                - switch hoses from mouthpiece back to chamber 
                - turn isoflurane from 2.5 to 0 and switch hoses so they bypass the isoflurane 
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Mammary Fat Pad Transplantation 
(Protocol obtained and adapted from L.A. Porter) 
 
 
1) Cells: 
-cells form tumours within 3 weeks 
-to prepare cells:        
 -wash with 1X PBS 
 -trypsinize 
                         -resuspend in 1X PBS ~ 5ml 
                         -count (inject 500 000 to 1 million cells/10 ml) 
                         -spin 1250xg for 2-5min at 4˚C 
                         -resuspend in appropriate amount of 1X PBS 
                                 -10 ml per gland 
                                 -2 glands per mouse 
                                 + extra 10 ml 
                         -keep cells on ice, bring to surgery room 
-cells should be proliferating, not confluent 
 
 
2) Mice: 
-retrieve mice from holding room; bring 2 cages for (1) holding and (2) recovery 
-place recovery cage on heating pad, and arrange the following items nearby: 
     -surgical drapes 
                -forceps (curved and straight) 
                -scissors 
                -syringe (25mL-Hamilton Cat. No. 1481318 and 1mL) 
                -back-up syringe 
                -stapler 
                -70% EtOH 
                -gauze 
                -eye drops (human eye drops work fine = "gel" kind is best) 
                -kimwipes 
-female mice can be kept 8/cage 
-male mice: 2/cage is best, 3/cage usually causes fights 
-keep males separate from females 
-we inject 4th pair of mammary glands 
-puberty starts in mice at ~ 4 weeks, so we want to clear the fat pad before then 
-pups are weaned at 21 days 
-fat pad clearing and injections are best performed at 21-24 days (up to 28 days) 
 
 
3) Injections 
-place warming pad (already heated via microwaving) on surgical table; place surgical 
drape over warming pad 
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To put mice under: 
-mouse should not be under for more than 20 min - after this time it may become more 
difficult to bring the animal back 
-1 min O2 
-isoflurane gas utilized as the anaesthetic of choice: flow rate established at 0.5 intervals 
for 30 seconds; increase 0.5 intervals every 20 seconds up to marking 2.5 
-move back down to 2.25 for surgery 
 
Injection: 
-when mouse is fully anaesthetized, move animal from cone to mouthpiece 
-inject 100 mL pain medication (buprenorphine-0.1 mg/mL) with 1mL needle, 253/8 
guage, under skin on back 
-give mouse eye drops (prevents drying out during surgery) 
-turn mouse over and wash abdomen with 70% EtOH 
-using forceps to pinch skin, make a vertical incision (should be less than 0.5 cm long) 
-pull back the skin on one side, using thumb to keep abdominal cavity in place 
      -may need to use forceps to pull abdominal cavity away from skin to expose 
      mammary gland 
-cut mammary gland horizontally under lymph node 
-use curved forceps to pull out bottom half of the fourth mammary gland 
-inject 10 ml of previously prepared cells into fat pad above lymph node 
      -use 25 mL 263/8 gauge needle (30 is too small) 
      -insert needle; pull up, slowly inject cells, while ensuring that no liquid leaks out, and 
      remove needle gently 
-use forceps to pull skin back 
-staple by holding skin together with forceps (should require at least 3 staples) 
 
To bring mice back: 
-remove mouthpiece, and put mouse back under cone (be careful not to clip the tail!) 
-decrease anaesthetic every minute by 0.5 intervals 
-keep mouse under 100% O2 until awake (may need to be nudged to wake up) 
-put mouse into recovery cage 
      -keep something in recovery cage for mouse to hide under (i.e., egg carton, paper 
       towel) 
 
Recovery: 
-no solid foods recommended on the day of surgery (Rob gives solid food anyway) 
      -can make a paste with mouse food and water to feed to them  
-no pain medication given after surgery 
-check mice a few hours after surgery to be sure wound has been closed completely 
-check mice again 24 h later 
      -look for holes, blood in cage, signs of illness, etc. 
-tumors may appear 7-21 days later, depending on cell type and concentration used 
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Mammary Gland Whole Mount Protocol 
(Protocol obtained and adapted from J. Rosen)1 
 
(1) 
Rosen, J. (2005, August 30). Mammary Gland Whole Mount Protocol. Retrieved 2009, 
from Rosen Lab Website: http://www.bcm.edu.rosenlab 
1. (a) Optional: Inject animals with BrdU 2 hours harvesting tissue 
(b) Fix tissue for 2 hours in fresh, cold 4% paramormaldehyde on ice. 
2. Rinse tissue in 70% ethanol until ready to stain (up to 2 weeks). 
 
All of the following steps are conducted by submerging tissue-cassettes containing glands 
into the solution. Thus, many glands can be processed in one jar at once. 
 
Defat 
         Acetone 3 x 30 min 
 
Note:
 This prohibits later immunohistochemical analysis by creating high background. If 
you want to try to do immunohistochemical on these glands, skip this step (or use the 
carmine alum protocol instead). 
 
Rehydrate 
         100%  EtOH  1 x 30 min 
          95%  EtOH  1 x 30 min 
 
Stain 
         Haematoxylin stain: 
              0.13 g FeCl3•6H2O 
              13.5 ml distilled water 
              Dissolve, and add 1.74 mL stock (10%) Harris hematoxylin 
              Add 200 ml 95% ethanol 
              Adjust pH to 1.25 with concentrated (12N) HCl (pH is critical)  
           
Note: 
Make stain fresh each time, and check that stain turns blue by putting tiny amount in 
a weigh boat and running under crude tap water. Stain should turn bright light blue. If not, 
throw out and try again. 
 
          Place glands in haematoxylin stain for 1.5 hours until whole gland looks purple. 
          If you did not defat in acetone (for future immunohistochemistry), stain overnight      
          to allow haematoxylin to permeate through fat. Monitor stain by holding gland to 
          the light. 
           
          Rinse in Crude tap H2O until water is clear. 
 
Destain 
          Acid ethanol  2 x 30 min 
          (200 ml 50% EtOH + 416 ul 12N HCl) 
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Note: 
Monitor destaining by holding gland up to the light. You should be able to clearly see 
blue epithelium with a fairly clear background. 
 
Dehydrate 
        70% EtOH 2 x 30 min 
        95% EtOH 2 x 30 min 
        100% EtOH  2 x 30 min 
              Complete dehydration of glands is critical for complete clearing. 
              Incomplete dehydration will result in brown background in the fat.  
              Use fresh 95% and 100% EtOH and do not take shortcuts. 
 
Clear 
        Xylene     2 x 1 hour (or can go overnight) 
 
Note: 
An alternate method of clearing the glands is to use BABB for 1-2 hours 
               BA = benzylalcohol 
               BB = benzylbenzoate 
               Mix chemicals in a 1:2 ratio (BA:BB) 
 
Note:
 leaving glands in BABB for extended time periods results in the lightening of the 
haematoxylin stain. 
 
   For imaging, remove gland from tissue-cassette and press between two glass slides and 
   flatten. Secure with mini binder clips and view under a dissecting microscope. 
 
   For long-term storage, transfer to methyl salicylate in glass scintiallation vials and 
   KEEP DARK. (If exposed to light, the blue will fade to brown) 
   
   Stock Haematoxylin (10%) 
- Harris haematoxylin (Fisher, powder) 
- Add 10g of powder to 100 ml of 95% ethanol, leave overnight stirring and it will go 
   into solution. Keep covered in foil. Let sit at least 3 weeks to 1 month for best stain. 
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Overview of Lentiviral Production – PEI-Mediated Protocol 
(Protocol obtained and adapted from Maimaiti, J. and L.A. Porter) 
 
J. Maimaiti. July 2009. 
Adapted from Segura, M.M. et al. (2007);
1 
Shore, A. and H.L. LaMarca (2008).
2
 
 
(1)
 Segura, M.M. et al. (2007) Production of lentiviral vectors by large-scale transient 
transfection of suspension cultures and affinity chromatography purification. 
Biotechnology and  Bioengineering, 98: 789-799. 
 
(2) 
Shore, A. and H.L. LaMarca (2008, March). Lentiviral Propagation. Retrieved 2009, 
from http://www.bcm.edu/rosenlab/protocols/Lentivirus%20Protocol.pdf 
 
Lentiviral particles should be treated as Risk Group Level 2 (RGL-2) organisms. 
Follow all published RGL-2 guidelines for handling and waste decontamination. Pipettes 
and media should be decontaminated in 10% bleach for at least 20 minutes before 
disposal. Please contact Jiamila prior to beginning this work to ensure all safety measures 
have been put into place. 
 
Aim of Procedure: To produce a concentrated lentiviral stock. 
 
Time scale. 
Day 1   Seed HEK293 Lenti-X Cells. 
Day 2   Co-transfect with pLB construct and lentiviral packaging vectors. 
Day 3   Change media on transfected cells. 
Day 4   Virus collection. 
Day 5   Virus collection.  
Day6   Virus collection, viral concentration, and storage. 
 
Routine Subculture of HEK293 Lenti-X Cells. 
     Maintain HEK293 Lenti-X cells in DMEM (DMEM, 10% FBS, 1% pen/strep). Cell 
cultures should be passaged three times a week between ratios of 1:4 and 1:6. Frequent 
passaging, in addition to maintenance of cell cultures at fewer than 80% confluence 
should be implemented to maintain a high transfection efficiency. Therefore do not allow 
cells to reach greater than 80% confluency.  
 
Day 1 – Seeding HEK293 Lenti-X Cells. 
     Seed HEK293 Lenti-X cells at a density of 3.5x10
6
 cells per 100mm dish in 8 ml 
DMEM + 10% FBS (no antibiotics). Cells should be seeded approximately 24 hours 
before transfection and incubated at 37°C, 5% CO2. Please note that cells should exhibit 
~60-70% confluency at the time of transfection. (recommended: split 1 plate of cells at 
60% confluency into 2 plates). 
 
Day 2 – Transfection. 
     Use 1mg DNA/ml media. 
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DNA: PEI ration =1:3 (i.e., if you need 8 mg DNA, you need 24 mg PEI) 
 
1. Prepare 10 ug DNA in 800ul DMEM (no FBS, no antibiotics). 
 
Transfer vector (pLB): pMDG (VSVG expressor): pMDL2 (gag-pol expressor): pRSV 
Rev = 2:1:1:1 
 
§ 4ug of Transfer vector (PEIZ) (1mg/ml)      4 ml 
§ 2ug pMDG (VSVG expressor)  (1mg/ml)     2 ml 
§ 2ug pMDL2 (gag-pol expressor) (1mg/ml)    2 ml 
§ 2ug pRSV Rev (1mg/ml)                             2 ml 
 
2. Add 30 mg PEI transfection reagent (10mg/ml) into DNA+DMEM mix, vortex 10 sec. 
3. Incubate DNA+DMEM+PEI mix at RT for 10 minutes. 
4. Add DNA+DMEM+PEI mix drop-wise onto overnight cell culture(s). 
5. Incubate cultures for 4-5 hours at 37°C, 5% CO2. 
6. After the 4 hour incubation period, replace the media with fresh DMEM+FBS (10%) 
and incubate overnight at 37°C, 5% CO2. 
 
Day 3, Day 4 and Day 5 – Virus Collection.  
§ Harvest lentiviral-containing supernatant after 24, 48, 72 hours of growing in a 50 
ml tube. After each collection, gently add fresh media to the cell culture(s), i.e., 8 
ml DMEM+10% FBS.  Store the virus at 4°C overnight. 
. 
Virus Concentration and Storage Notes 
§ Syringe filter-sterilize each of the collected viral suspensions using a 30 ml 
syringe and a 0.45 ml syringe filter. 
§ Transfer filtered viral suspension into ultrasound centrifuge tube (at most, 33 ml). 
§ Spin virus at 25,000 rpm for 3 hours at 4˚C (use Beckman ultrasound centrifuge). 
§ Decant the supernatant and allow the centrifugation tubes to rest upside down on a 
paper towel to remove as much liquid as possible. Kim wipes/tissue may also be 
used to wipe around the tube. Make sure to remove as much supernatant as 
feasible. 
· Turn centrifugation tubes right-side up, immediately. Resuspend viral pellet in 
300 ml 1X PBS that has been filter sterilized into the tube without pipetting.  
· Allow the tubes to incubate on ice for 30 minutes or overnight. 
· Following the incubation period, carefully pipette up and down several times. 
From this point on, the virus must be treated very gently, so as not to damage the 
viral membrane. 
· Remove the viral supernatant, aliquot into the necessary number of cryovials (25 
ml aliquot for each vial) and store at -80°C for future utilization.  
 
 
 
133 
 
Lentivirus: Titering Your Lentiviral Stocks 
(Protocol obtained and adapted from Maimaiti, J. and L.A. Porter) 
 
 
DAY 0: 
Plate 293T cells. 
 
Plate 7.0x10
4
 cells/well (24-well plate) in a final volume of 500 ml/well in 10% FBS/ 
DMEM media per well, and designate the following: 
 
 a) 1 well → count cells prior to transduction 
 b) 1 well → untransduced control 
 c) 4 wells for each virus → serial dilutions 
 
Incubate at 37°C overnight. 
 
DAY 1: 
Transduce 293T cells. 
 
Cells should be ~60% confluent at the time of transduction. 
 
1. Count the number of cells present in 1 well (usually 3x105 cells immediately prior 
to transduction). 
2. Prepare 10-fold serial dilutions ranging from 10-2 to 10-4. Depending on the 
concentration of your virus, you may need to expand this range (i.e., 10
-2
 to 10
-12
). 
 Dilute the virus in DMEM (no FBS and no antibiotics): 
  2.5 ml stock virus + 247.5 ml media → 10
-2
 
  25 ml 10
-2
 virus + 225ml media → 10
-3
 
  25 ml 10
-3
 virus + 225ml media → 10
-4
 
  25 ml 10
-4
 virus + 225ml media → 10
-5
  
3. Aspirate media from 293T cells. 
 Add 200 ml of diluted virus to each designated well, as previously outlined. Be 
 sure to include 1 untransduced well. 
 Incubate cells at 37°C, 5%C02 overnight 
 
Note:
 You may supplement your virus dilution media with polybrene at 8 mg/ml (our stock 
is 1mg/ml). I add 0.2 ml polybrene into each well or prepare 1 ml media with 8 ml of 
polybrene to be utilized for viral dilution. 
 
DAY 2: 24 hours post-transduction. 
4. Aspirate media containing virus and replace with 500 ml of fresh 10% FBS/ 
DMEM. 
 Incubate cells at 37°C for an additional 48 hours at 5% CO2. 
 
DAY 4: 72 hours post-transduction. 
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5. Visualize the percentage of GFP expression utilizing GFP-fluorescence 
microscopy. GFP expression should range between 100% and 0%. Pick the wells 
that have about 5-20% GFP+ cells in order to titre the virus by flow cytometry. 
§ Collect the cells in 1ml 1X PBS and centrifuge at 3000 rpm for 5 minutes. 
§ Resuspend cell pellet in 400 ml 1X PBS and place into flow cytometry tubes for 
subsequent analysis and viral titration. 
 
Calculate titre: use numbers from samples that were between 5-20% GFP+ to ensure that 
you are within the acceptable linear range. 
      T = (P x N) 
 (D x V) 
 
T = titre (TU/ml) 
P = % GFP+ cells (e.g., N = 0.2 for 20% GFP+ cells) 
N = number of cells at the time of transduction 
D = dilution factor (e.g., 10
-3
 = 0.001) 
V = volume of viral inoculum (0.2 ml) 
 
Note: Formula for virus titer calculation:  
 
titre = {(F × Cn) /V} × DF 
 
F  the frequency of GFP-positive cells determined by flow cytometry  
Cn  the total number of target cells infected  
V the volume of the inoculum 
DF the virus dilution factor  
 
Example: 
Dilution  
0  10
-1
  10
-2
  10
-3
  10
-4
  
DF  0  10  100  1000  10000  
F  0 (0%)  0.12 (12%)  0.01 (1%) 0.003 
(0.2%)  
0.0004 
(0.05%)  
Cn  2 x 10
5
  2 x 10
5
  2 x 105  2 x 105  2 x 105  
V (ml)  1  1  1  1  1  
Titre (TU/ml)  0  2.4 x 10
5
  2 x 10
5
  6 x 105  8 x 105  
 
Thus, the titre of the lentiviral stock is 2.2 x 105 TU/ml (i.e. .average of 2.4 x 10
5
 and 2 x 10
5
). 
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Lentiviral Transduction 
(Protocol obtained and adapted from Maimaiti, J. and L.A. Porter) 
 
A.  Preparation 
a. Prepare mammalian cells so that they are growing exponentially and are no more 
than 70-80% confluent before transduction.  
b. Prepare a stock solution of polybrene at 1 mg/ml in water. 
c. 96-well plate. 
B. Methods 
 
Day 1.  
     Add 1.6 x 10
4
 cells in fresh media to the number of wells needed for each construct in 
a 96-well plate. Duplicate or triplicate wells should be used for each lentiviral construct. 
Incubate 18-20 hours at 37°C in a humidified incubator in an atmosphere of 5% CO2. 
 
Note:
 Growth rates of cells vary greatly. Adjust the number of cells plated to accommodate 
a confluency of 70% upon transduction. Also, account for the length of time the cells will 
be growing for before downstream analysis, when determining the plating density. 
 
Day 2.  
     Remove media from wells. Add 110 ml media and polybrene (final concentration of 8 
mg/ml) to each well. Gently swirl the plate to mix. Add 2-15 ml of lentiviral particles to 
appropriate wells. Gently swirl the plate to mix. Incubate 18-20 hours at 37°C in a 
humidified incubator, in an atmosphere of 5% CO2. 
 
Note: 
When transducing a lentiviral construct into a cell line for the first time, a range of 
volumes or MOIs should be tested. 2, 5, 10, and 15 ml of lentiviral particles per 1.6 x 10
4
 
cells or MOIs of 0.5, 1, and 5 should be used to determine the optimal transduction 
efficiency and knockdown for each cell line (see Additional Notes). 
 
Note:
 Cells may be incubated for as little as 4 hours before changing the media containing 
lentiviral particles. Overnight incubation may be avoided when toxicity of the lentiviral 
particles are of a concern. 
 
Day 3.  
     Remove the media containing lentiviral particles from wells. Add fresh media to a 
volume of 120 ml to each well. 
 
Note:
 For cell types that do not strongly adhere to the plate, 100 ml of media may be 
removed and replaced with 100 ml fresh media. 
 
Day 4.  
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     Remove media from wells. Add fresh media containing puromycin. The appropriate 
concentration of puromycin for each cell type is different. If the concentration for the 
desired cell type is unknown, a titration experiment must be performed. Typically, 2-10 
mg/ml are sufficient to kill most untransduced mammalian cell types. 
 
Day 5 and on.  
     Replace media with fresh media every 3-4 days until colonies can be identified under 
GFP-fluorescence microscopy. Pick a minimum of 5 colonies and expand each clone to 
assay for knockdown of the target gene. 
 
     A puromycin titration (kill curve) should be performed when working with a new cell  
     type. 
 
DAY 1  
§ Plate target cells in a 12-well plate 24 hours prior to viral infection. 
§ Add 1 ml of complete optimal medium (with serum and antibiotics) and incubate 
cells overnight. The cells should be approximately 50% confluent on the day of 
infection (Day 2). 
NOTE:
 It is possible to use other plate formats for transduction, as well. In this case, 
the amount of cells should be adjusted depending on the growth area of the well or 
plate. 
 
DAY 2 
§ Prepare a mixture of complete medium with Polybrene® (sc-134220) at a final 
concentration of 5 µg/ml. 
§ Remove media from plate wells and replace with 1 ml of Polybrene-media 
mixture per well (for 12-well plate). 
NOTE:
 Polybrene is a polycation that neutralizes charge interactions to increase 
binding between the pseudoviral capsid and the cellular membrane. The optimal 
concentration of Polybrene depends on cell type and may need to be empirically 
determined (usually in the range of 2-10 µg/ml). Excessive exposure to Polybrene 
(>12 hr) can be toxic to some cells. 
· Thaw lentiviral particles at room temperature and mix gently before use. 
· Infect cells by adding the shRNA Lentiviral Particles to the culture. 
· Swirl the plate gently to mix and incubate overnight. The amount of viral particles 
to use varies greatly depending on the characteristics of the cell line used. 
NOTE:
 Keep thawed shRNA lentiviral particles on ice. Repeated freeze-thaw cycles 
and prolonged exposure of the particles to ambient temperatures may result in 
decreased viral titres. 
137 
 
 
NOTE:
 When transducing an shRNA lentiviral construct into a cell for the first time, 
we suggest using several volumes of shRNA lentiviral particle stock. In addition, 
we recommend to include one well with cells transduced with Control shRNA 
Lentiviral Particles (sc-108080). 
 
NOTE:
 Use co-GFP Control Lentiviral Particles (sc-108084) to measure the 
transduction efficiency. 
 
DAY 3  
§ Remove the culture medium and replace with 1 ml of complete medium (without 
Polybrene). Incubate cells overnight. 
DAY 4  
§ To select stable clones expressing the shRNA, split cells 1:3 to 1:5, depending on 
the cell type, and continue incubating for 24-48 hours in complete medium. 
DAY 5-6 and forward  
§ Select stable clones expressing the shRNA via GFP expression. 
§ Replace media with fresh media every 3-4 days, until fluorescent colonies can be 
identified. Pick several colonies, expand them, and assay them for stable shRNA 
expression. 
NOTE:
 For shRNA expression analysis by 10% SDS-PAGE, prepare cell lysates as 
follows:  
§ Wash cells once with 1X PBS. 
§ Lyse cells in 100 µl of a 1:1 mixture of 2x Electrophoresis Sample Buffer (sc-
24945) and RIPA Lysis Buffer (sc-24948) by gently rocking the 12-well plate or 
by pipetting up and down. 
§ Sonicate the lysate on ice if necessary. 
C. Additional Notes 
 
Calculation of MOI Value 
Multiplicity of Infection (MOI): Multiplicity of Infection is the number of transducing 
lentiviral particles per cell. It is highly recommended that for each new cell type to be 
transduced, a range of MOIs should be tested. This will determine the optimal amount of 
lentiviral supernatant needed for efficient transduction of each cell line used. 
To calculate: 
(Total number of cells per well) x (Desired MOI) = Total transducing units needed (TU) 
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(Total TU needed) / (TU/ml reported on C of A) = Total ml of lentiviral particles to add 
to each well 
Determining the Optimal Puromycin Concentration  
Each cell line responds differently to puromycin selection. Addgene recommends that you 
determine the optimal puromycin concentration for your cell line before initiating your 
experiment.  
Day 1 
a. Plate target cells (2x10
5
cells/well) in 6 well plates and grow at 37
o
 C, 5% CO2 
overnight.  
 
Day 2 
b. The target cells should be approximately 80-90% confluent.  
c. Dilute puromycin in the preferred culture media for your target cells. The final 
concentration of puromycin should be from 1-10 μg/mL, in 1 μg/mL increments.  
d. Label plates from 1-10 and add appropriate puromycin-containing media to 
cells.  
Days 3 + 
e. Examine cells each day and change to fresh puromycin-containing media every 
other day.  
f. The minimum concentration of puromycin that results in complete cell death 
after 3-5 days is the concentration that should be used for selection in your 
experiments. (You may wish to repeat this titration with finer increments of 
puromycin to determine a more precise optimal puromycin concentration.)  
D. Solutions 
Hexadimethrine Bromide (Polybrene). Prepare a 1mg/mL solution of polybrene (Sigma-
Aldrich catalog #H9268) in 0.9% NaCl. Autoclave to sterilize. Stock solution is stable at 
4
o
C for up to one year. The powder form of polybrene is stable at 4
o
C for several years.  
Protamine Sulfate. Store protamine sulfate (MP Biomedicals catalog #194729) at 4
o
C. 
Freely soluble in hot water and slightly soluble in cold water.  
Puromycin. Prepare a 50mg/mL stock solution of puromycin (Sigma-Aldrich catalog 
#P8833) in distilled water. Sterilize by passing through a 0.22 μm filter. Store aliquots at  
-20
o
C.  
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